High fat diet induces chromatin remodelling and alters the expression of the diabetogene Ped/Pea-15 by Vastolo, Viviana
 UNIVERSITY OF NAPOLI FEDERICO II
 
Doctorate School in Molecular Medicine
 
Genetics and Molecular Medicine
Coordinator: Prof. Lucio Nitsch
 
“HIGH FAT DIET INDUCES CHROMATIN 
REMODELLING AND ALTERS THE 
EXPRESSION OF THE DIABETO
 
 
Doctorate Program in 
 
XXVI Cycle 
GENE 
Ped/Pea-15” 
Viviana Vastolo 
 
Napoli 2014 
 
 
 
 
2 
 
 
 
 
 
 
 
 
 
 
 
 
 
“HIGH FAT DIET INDUCES 
CHROMATIN REMODELLING AND 
ALTERS THE EXPRESSION OF THE 
DIABETOGENE Ped/Pea-15” 
 
 
 
 
 
 
 
3 
 
TABLE OF CONTENT 
Page 
LIST OF PUBLICATIONS  5 
ABSTRACT  6 
1 BACKGROUND 7 
1.1 Epigenetics  7 
1.2 Epigenetic modifications 7 
1.2.1 Histone modifications  8 
1.3 Epigenetics as a link between metabolism and transcription 11 
1.4 Type 2 Diabetes 12 
1.4.1 Ped/Pea-15 gene 15 
1.4.2 Ped/Pea-15 and glucose metabolism 16 
1.4.3 Ped/Pea-15 transcriptional regulation 17 
2 AIMS OF THE STUDY 19 
3. MATERIALS AND METHODS 20 
3.1 Animal study 20 
3.2 Glucose tolerance test (GTT) 20 
3.3 Insulin tolerance test (ITT) 20 
3.4 Glucose stimulated insulin secretion (GSIS) 21 
3.5 Biochemical parameters 21 
3.6 Western blot analysis  21 
3.7 Real time PCR 21 
3.7.1 Cloning of the Real time amplification products of  
Ped/Pea-15 and Gapdh for copy number analysis 22 
3.8 Formaldehyde-Assisted Isolation of Regulatory Elements (FAIRE) 22 
3.9 Micrococcal Nuclease assay (MNase) 23 
4 
 
3.10 Chromatin Immunoprecipitation (ChIP) 24 
3.11 Statistical analysis 24 
4 RESULTS AND DISCUSSION 25 
4.1 Animal study design 25 
4.2 Metabolic characteristics of standard and high fat diet mice 26 
4.3 Effects of high fat diet on Ped/Pea-15 levels in insulin target tissues 29 
4.4 Effects of high fat diet on chromatin remodeling at  
Ped/Pea-15 promoter 31 
4.5 Effects of high fat diet on nucleosomes positioning at 
 Ped/Pea-15 promoter 33 
4.6 Effects of high fat diet on histone modifications at  
Ped/Pea-15 promoter 35 
4.7 Tissue-specific effect of high fat diet on a distal  
Ped/Pea-15 promoter region 39 
5 CONCLUSIONS 45 
6 AKNOWLEDGEMENTS 46 
7 REFERENCES 47 
 
 
 
 
 
 
 
 
 
 
5 
 
LIST OF PUBLICATIONS 
This dissertation is based upon the following publication: 
1. Ungaro P, Mirra P, Oriente F, Nigro C, Ciccarelli M, Vastolo V, Longo 
M, Perruolo G, Spinelli R, Formisano P, Miele C, Beguinot F. 
Peroxisome proliferator-activated receptor-γ activation enhances 
insulin-stimulated glucose disposal by reducing ped/pea-15 gene 
expression in skeletal muscle cells: evidence for involvement of 
activator protein-1. J Biol Chem. 2012 Dec 14;287(51):42951-61 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
6 
 
ABSTRACT 
Environmental factors interact with the genome to influence gene expression, 
tissue function and also disease risk. External stimuli may affect the phenotype 
through epigenetic mechanisms that provide an interface with the genome. 
Phosphoprotein Enriched in Diabetes/ Phosphoprotein Enriched in Astrocytes 
(Ped/Pea-15) is a gene commonly overexpressed in Type 2 Diabetes 
individuals and in their euglycaemic offspring. Furthermore, its overexpression 
impairs glucose tolerance and insulin sensitivity in transgenic mouse models. 
However, whether external cues can affect its expression remains unclear. 
Therefore, the aim of this study is to evaluate whether the administration of a 
high fat diet (HFD) in mice could affect Ped/Pea-15 expression and whether 
chromatin remodelling and epigenetic modifications take part in this 
regulation. In this work, I demonstrated that high fat diet increases Ped/Pea-15 
levels in the skeletal muscle and adipose tissues but not in the liver, 
accompanied by a chromatin reorganization assessed by Formaldehyde 
Assisted Isolation of Regulatory Elements (FAIRE) assays. Moreover, 
chromatin remodelling upon high fat diet does not result in nucleosome 
depletion but in changes in histone modifications. In particular, increased gene 
transcription well correlates with increased H4 acetylation and histone H3 
dimethylation of lysine 4 on Ped/Pea-15 promoter, two active histone marks. 
In addition, a specific promoter region acquires typical features of enhancer 
elements such as monomethylated lysine 4 (H3K4me1) and acetylated lysine 
27 (H3K27Ac) on histone H3 in the skeletal muscle tissue of HFD mice 
compared to STD mice. These two histone marks lack instead in the liver of 
both HFD and STD mice. These findings provide evidence for environmentally 
induced changes at Ped/Pea-15 promoter and, for the first time, highlight the 
presence of a distal, tissue-specific, regulatory element potentially involved in 
the upregulation of Ped/Pea-15 upon high fat diet administration.  
Since direct evidence linking specific environmental cues and metabolic 
disorders are still limited, addressing this issue will provide new insight into 
the molecular basis of type 2 diabetes as well as create novel translational 
perspective. 
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1. BACKGROUND 
1.1 Epigenetics 
Genetic information encoded in DNA is largely identical in every cell of an 
eukaryote. However, cells in different tissues and organs can have widely 
different gene expression patterns and can exhibit specialized functions. 
Moreover, specific gene expression patterns need to be appropriately induced 
and maintained and also need to respond to developmental and environmental 
changes. Therefore, most of the differences among specialized cells are 
epigenetic and non genetic. 
The word “epigenetics” was termed in the early 1940s to describe the events 
that could not be wholly explained by traditional genetics. Conrad Waddington 
defined epigenetics as “the branch of biology which studies the causal 
interactions between genes and their products which bring the phenotype into 
being” (Choudhuri, 2011). The epigenetic field now actively uncovers the 
molecular mechanisms underlying these phenomena, and epigenetics has been 
defined today as “the study of changes in gene function that are mitotically 
and/or meiotically heritable and that do not entail a change in DNA sequence” 
(Jaenisch & Bird, 2003). In other words, epigenetics is the study of changes in 
gene expression or phenotype, caused by mechanisms other than DNA 
sequences.  
1.2 Epigenetic modifications 
The first types of epigenetic systems are the chromatin-marking system and 
the DNA methylation system, referred as “epigenetic marks”. The most studied 
epigenetic modifications include DNA methylation, noncoding RNAs and 
histones modifications. 
DNA methylation occurs principally at a cytosine base, mainly in CpG 
dinucleotides in vertebrates; it is a simple covalent chemical modification, 
resulting in the attachment of a methyl (CH3) group at the 5' carbon position of 
the cytosine ring. Generally, DNA methylation is associated with gene 
repression (de Groote et al, 2012; Maunakea et al, 2010). 
Noncoding RNAs (ncRNAs) are another type of epigenetic actors (Morris, 
2009). NcRNAs regulate gene expression by cis- and trans-acting mechanisms 
(Rassoulzadegan et al, 2006). Some ncRNAs act in concert with components of 
chromatin and the DNA methylation machinery to establish and/or sustain gene 
silencing (Zaidi et al, 2011). They can also regulate RNA processing, mRNA 
stability, translation, and protein stability and secretion. Indeed, they can 
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contribute to gene splicing, nucleotide modification protein transport and 
regulation of gene expression. Non coding-RNAs include micro-RNAs 
(miRNAs) that can regulate gene expression by post-translational silencing of 
gene expression and long noncoding RNAs (lncRNAs) can act as tethers and 
guides to bind proteins responsible for modifying chromatin and mediate their 
deposition at specific genomic locations (Kawaji et al, 2008). 
Finally, a large number of different post-translational modifications (PTMs) 
can occur on histone tails. These modifications affect inter-nucleosomal 
interactions and thus affect the overall chromatin architecture contributing to 
the control of gene expression through influencing chromatin compaction or 
signaling to other protein complexes (Kouzarides, 2007). 
1.2.1 Histone modifications 
DNA in eukaryotic cells is organized in a DNA-protein complex known as 
chromatin. Nucleosome is the fundamental unit of chromatin and it is 
composed of two copies each of the four core histone proteins (H3, H4, H2A, 
H2B) around which 147 base pairs of DNA are wrapped (Wellen et al, 2009) 
(Figure 1). The organization into nucleosomal arrays only results in a 5-fold 
compaction of DNA. The linker histone H1 is associated with the linker DNA 
as well as with the nucleosome core particle itself, and thus plays an important 
role in the compaction of DNA beyond the nucleosomal level. 
 
Figure1. Eukaryote genome packaging: A histone octamer is the eight protein 
complex found at the center of a nucleosome core particle. It consists of two copies of 
each of the four core histone proteins (H2A, H2B, H3 and H4) surrounded by 147 
base pairs of DNA wrapped in a superhelical. The organization into nucleosomal 
arrays results in a 5-fold compaction of DNA (10-nm fibre). The linker histone H1 is 
associated with the linker DNA as well as with the nucleosome core particle itself, and 
thus plays an important role in the higher compaction of DNA (30-nm fiber). 
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histidines residues and it may be one of three different forms: mono-, di-, or 
trimethyl for lysines, mono- or di- (asymmetric or symmetric) for arginines, 
and histidines have been reported to be monomethylated (Greer & Shi, 2012). 
The most extensively studied histone methylations include that on lysine and 
arginine residues on histones H3 and H4. However, many other basic residues 
throughout all the histone proteins have also been described (Young et al, 
2010). In general, histone methylation is more stable than other PTMs, and it 
was originally thought to be irreversible. However, the discovery of a 
demethylase revealed that it is, in fact, reversible (Shi et al, 2004). Both lysine 
and arginine methylation can be either activating or repressive for gene 
expression (Bannister & Kouzarides, 2005; Lee et al, 2005). Regarding lysine 
methylation, three sites are implicated in activation of transcription: H3K4, 
H3K36 and H3K79. In contrast, H3K9, H3K27 and H4K20 are associated to 
gene repression. More specifically, lysine 4 can be mono-, di- and tri-
methylated. To this regard, a particular insight is the correlation between some 
chromatin marks and specific regulatory elements. Indeed, promoter regions 
are marked by trimethylation (H3K4me3) and associated with RNA 
polymerase II, while distant regulatory regions - like enhancers- are 
characterized by the monomethylation at the same position (H3K4me1) (Visel 
et al, 2009). Moreover, many H3K4me1 marked regions can gain the H3K27 
acetylation mark, probably recruiting histone acetyltransferases such as p300. 
This additional mark results in a switch from a “poised” to “active” status of 
distal regulatory elements (Ostuni et al, 2013). 
Regarding histone acetylation, of all the known modifications, has the most 
potential to unfold chromatin since it neutralizes the basic charge of the lysine. 
Acetylation occurs at lysine residues on the amino-terminal tails of the 
histones, thereby neutralizing the positive charge of the histone tails and 
decreasing their affinity for DNA (Struhl, 1998). As a consequence, histone 
acetylation alters nucleosomal conformation which can increase the 
accessibility of transcriptional regulatory proteins to chromatin templates 
(Kouzarides, 2007). Thus this modification is almost invariably associated with 
activation of transcription. Moreover, it has been demonstrated that acetylation 
of H4K16 has a negative effect on the formation of a 30-nanometer fiber and 
the generation of higher-order chromatin structures (Shogren-Knaak et al, 
2006). 
Phosphorylation is another modification that may well have important 
consequences for chromatin compaction via charge changes. Some evidence 
highlights it in mitosis, apoptosis, and gametogenesis (Rossetto et al, 2012).  
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This vast array of modifications gives enormous potential for functional 
responses, but not all these modifications will be on the same histone at the 
same time (Siebel et al, 2010). The timing of the appearance of a modification 
will depend on the signaling conditions within the cell. Moreover, these 
modifications regulate one another, providing regulatory cross-talk (Latham & 
Dent, 2007). Thus, one modifications can influence the occurrence of one or 
more subsequent modifications either in cis, on the same histone molecule, or 
in trans, between histone molecules or across nucleosomes (Figure 3). 
 
 
Figure 3 Cross-talk between histone modification in cis and in trans. 
Modifications on histone tail makes a cross-talk between different residues. The 
positive influence over another is shown by an arrow and the negative effect by a dish-
line. 
The histones-DNA interactions set a critical stage for the regulation of the 
transcription of genes by influencing the DNA accessibility to the cell 
transcriptional machinery elements. In this scenario, all the post-translational 
modifications of histone proteins, also known as histone code, provide a 
platform to accommodate the binding of factors regulating the chromatin 
function. Therefore, alterations in these epigenetic modifications could lead to 
the deregulation of gene transcription. 
1.3 Epigenetics as a link between metabolism and transcription 
Metabolic homeostasis is maintained by tightly controlled transcriptional 
mechanisms. In turn, transcriptional control is achieved through complex 
molecular events in which take part transcription factors, the basal 
transcriptional machinery and co-regulatory proteins (Feige & Auwerx, 2007). 
These co-regulators are proposed to act as metabolic sensors, able to translate 
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change in metabolism into change in gene expression by affecting the activity 
of transcription factors, as well as changing the structure of the epigenome 
(Haberland et al, 2009). In particular, nutritional information may influence the 
epigenome by directly affecting the activities of epigenetic modifiers (Teperino 
et al, 2010). For example, the loss of function of the histone demethylase, 
Jhdm2a, associated with obesity, decreased the expression of metabolically 
active genes in the skeletal muscle tissue, and impaired cold-induced uncopling 
protein 1 expression in brown adipose tissue in rodents (Tateishi et al, 2009). 
Moreover, the nicotinamide adenine dinucleotide (NAD+)-dependent sirtuins 
are involved in epigenetic controls of metabolism (Schwer & Verdin, 2008). 
Indeed, energy-rich substrates (e.g. carbohydrates, fat) are converted into ATP 
increasing the levels of some metabolites, such as acetyl-CoA, nicotinamide 
adenine dinucleotide (NAD+), S-Adenosyl-methionine (SAM), alpha-
ketoglutaric acid and flavin adenosine dinucleotide. 
These metabolities are used as coenzymes by chromatin-modifying enzymes. 
For example, all the three classes of histone methyltransferases use S-
Adenosyl-methionine to transfer methyl groups (Smith & Denu, 2009). Indeed, 
also demethylases use metabolites as cofactors; lysine-specific demethylase 1 
(LSD-1) is FAD-dependent, whereas JmjC enzymes feature α-ketoglutarate-
dependent activity (Shi et al, 2004; Tsukada et al, 2006). Moreover, it has 
recently been suggested that glucose availability can affect histone acetylation 
in an ATP-citrate lyase-dependent manner, further linking metabolic 
homeostasis to epigenetic regulation (Wellen et al, 2009). 
Thus, metabolic deregulation alters coenzymes biosynthesis that, in turn, 
affects the activity of chromatin modification enzymes leading to an alteration 
in gene expression.  
Therefore, epigenetics may play a key role in the causation and in the 
progression of many common multifactorial diseases, such as diabetes and 
obesity, both associated with an aberration of cellular energy metabolism. 
1.4 Type 2 Diabetes 
Type 2 diabetes (T2D) is a disease of impaired glucose homeostasis and 
insulin action with an etiology that encompasses genetic, cellular and 
environmental factors. It results from the imbalance between glucose 
production and glucose utilization reflecting the imbalance between insulin 
resistance of muscle, adipose tissue, and liver and the secretion of insulin by 
the β-cells mass (Lin & Accili, 2011; Taylor, 2008; Weyer et al, 1999) (Figure 
4). 
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T2D is the most common type of diabetes, accounting for 90% of all forms of 
the disease. It is typical of the adult age, but it is now also increasing among 
young adults. Rarely, T2D is an isolated condition; it is most often one of set of 
features called metabolic syndrome, including obesity, hypertension, 
dyslipidemia.  
 
 
Figure 4 Factors involved in pathophysiology of type 2 diabetes Both genetic and 
environmental factors cooperate in the development of insulin resistance. At the onset 
of the disease, β-cells increase insulin release to overcome the reduced efficiency of 
insulin action, thereby maintaining normal blood glucose level. By contrast, when β-
cells fail to compensate, impaired glucose tolerance and, finally, type 2 diabetes occur. 
As mentioned above, type 2 diabetes is a complex trait influenced by genetic 
and environmental factors. The identification of the genes involved in T2D has 
been an arduous task for geneticists, devoting a large amount of effort to this 
goal. Thus, several candidate-gene studies have been performed that were 
successful in identifying some monogenic familial forms of T2D such as 
maturity onset diabetes of the young (MODY), mitochondrial diabetes and 
neonatal diabetes (Barroso, 2005). Unfortunately, these monogenic forms of 
diabetes represent only a small fraction of the disease. However, linkage and 
associations studies on common form of T2D provided inconsistent results. 
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Only PPARg, KCKJ11 and TCF7L2 were identified as established genes 
associated with the frequent forms of the disease (Zeggini, 2007). 
Thereafter, genome-wide association studies (GWASs) were supposed to 
provide a novel understanding of T2D causation. Multiple loci markers have 
been found through these studies that heightens risk for T2D when present 
(Sanghera & Blackett, 2012). While GWAS has enabled the generation of new 
hypotheses regarding the relation of genetics to T2D, the genetic markers 
found have poor penetrance. Further, these genetic markers do not explain a 
significant portion of T2D in context of other factors. Perhaps the lack of 
impact of GWAS comes from not comprehensively considering environmental 
factors in the disease. Indeed, while genetics play a large role, specific 
environmental factors are also emerging as risk factors for the disease. 
Environment is even more complex than genetics, since it is made of a 
continuous flow of space-time exposures from the time of one-cell zygote to 
the time of disease onset. A first environmental-wide association study 
(EWAS) was performed in a T2D cohort and identified potential environmental 
factors with effect sizes comparable to loci found by GWAS (Patel et al, 2010). 
Environmental contributions to the development of type 2 diabetes potentially 
include exposures such as a suboptimal in utero environment, low birth weight, 
obesity, nutrients, inactivity, advancing age. These environmental perturbations 
can lead to a disease phenotype by affecting gene expression through 
epigenetic modifications. 
Moreover, the incidence of type 2 diabetes has rapidly increased over the past 
several decades and is now reaching epidemic proportions across the globe. 
The World Health Organization (WHO) has declared that a diabetes epidemic 
is underway. In 1985, an estimated 30 million people worldwide had diabetes. 
By 1995, this number had shot up to 135 million, and by 2005 reached an 
estimated 217 million. Alarmingly, the WHO predicts that this will increase to 
at least 366 million by 2030 (Smyth & Heron, 2006). 
The threatened epidemic of T2D is largely driven by the increase in obesity. 
Both, obesity and type 2 diabetes are becoming the normal metabolic fate of a 
large fraction of human populations. This escalation in frequency certainly has 
a widespread genetic background, but several evidence suggest its main 
sources in environmental changes. In addition, genetic models to explain the 
epidemic obesity are inadequate because the emergence over the past 30 years 
has been too rapid to allow for the appearance of new mutant genes. 
Accordingly, epigenetic modifications of gene structure through nutritional and 
physiological stress provide mechanisms for inducing obesity and type 2 
diabetes that are independent of new mutations to the genome. For these 
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reasons, epigenetics has become a leading causative candidate for the 
causation, and possibly inheritance, of obesity and type 2 diabetes. However, 
the knowledge about epigenetic mechanisms associated to type 2 diabetes still 
remains limited. Therefore, it will be a great challenge addressing this issue, 
making possible to test epigenetic drugs as a putative novel treatment of 
diabetes as well as its complications. 
1.4.1 Ped/Pea-15 gene 
Posphoprotein Enriched in Diabetes/Phosphoprotein Enriched in Astrocytes 
(Ped/Pea-15) gene maps on human chromosome 1q21-22, is highly conserved 
among mammals, and is ubiquitously expressed in human tissues (Danziger et 
al, 1995). It encodes for a 15-kDa cytosolic multifunctional protein. Indeed, 
PED/PEA-15 protein has initially been identified in [32P]phosphate-labeled 
astrocytes and for this reason it was named Phosphoprotein Enriched in 
Astrocytes (Araujo et al, 1993). Using a differential cloning strategy, 
PED/PEA-15 was later found to be overexpressed in skeletal muscle and fat 
tissues as well as in cultured skin fibroblasts of type 2 diabetic subjects, but not 
in type 1 diabetic patients (Condorelli et al, 1998). Therefore, it has been 
renamed Phosphoprotein Enriched in Diabetes. 
PED/PEA-15 is a scaffold protein regulating the function of a number of 
signaling proteins and effectors. It is highly regulated and it can be 
phosphorylated at Ser104 by protein kinase C and at Ser116 by calcium-
calmodulin kinase II (CaMKII) and by Akt/PKB. Thus, PED/PEA-15 exists in 
three differentially phosphorylated forms: unphosphorylated, mono-
phosphorylated and bi-phosphorylated. It exerts a broad anti-apoptotic function 
by interfering with both intrinsic and extrinsic pathways (Condorelli et al, 
2002; Condorelli et al, 1999; Peacock et al, 2009; Trencia et al, 2004). In 
addition, PED/PEA-15 is involved, at least in part, in the regulation of cellular 
proliferation by controlling the extracellular signal-regulated kinase (ERK) 
pathway (Callaway et al, 2007; Formstecher et al, 2001). There are also 
evidence in literature regarding the role of PED/PEA-15 in neoplastic 
transformation. Indeed, in tumors driven by oncogenic Ras, PED/PEA-15 acts 
as an ERK1/2 nuclear export factor and exerts tumor suppressor activity 
(Gaumont-Leclerc et al, 2004). On the other hand, it has been demonstrated 
that high levels of PED/PEA-15 expression associate with development of 
malignancy: Ped/Pea-15 gene is overexpressed in human gliomas and in 
mammary carcinomas (Hao et al, 2001; Hwang et al, 1997; Stassi et al, 2005; 
Xiao et al, 2002). It is possible that the differences in the effects mediated by 
PED/PEA15 could depend on its phosphorylation state and on the cellular 
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context. Finally, Ped/Pea-15 emerged as a key regulator of glucose 
metabolism. 
1.4.2 PED/PEA-15 and glucose metabolism 
Earlier findings in humans evidenced that Ped/Pea-15 gene is overexpressed 
in skeletal muscle and fat tissues as well as in cultured skin fibroblasts from 
individuals with type 2 diabetes (Condorelli et al, 1998). Indeed, Ped/Pea-15 
overexpression represents a common trait among type 2 diabetics, because 
approximately one-third of the individuals diagnosed with the disorder exhibit 
Ped/Pea-15 expression levels higher than 2 SD above the mean in the control 
subjects (Condorelli et al, 1998). 
Further functional analysis in cultured skeletal muscle and adipose cells 
demonstrated that increased expression of PED/PEA-15 causes resistance to 
insulin action in glucose uptake. In particular, PED/PEA-15 binds 
phospholipase D1 (PLD1) and enhances its stability and activity thus 
increasing diacylglycerol (DAG) levels, thereby activating the dyacylglycerol-
sensitive protein kinase C α (PKCα). This effect, in turn, prevents the 
activation of the PKCζ isoform, a major activator of glucose transporter 4 
(GLUT4) vescicle translocation toward the plasma membrane (Condorelli et al, 
2001; Zhang et al, 2000) (Figure 5). 
 
 
Figure 5 Role of PED/PEA-15 in glucose metabolism. Overexpression of 
PED/PEA-15 binds phospholipase D, thereby increasing its stability and 
diacylglycerol levels. The consequent increase of PKCα activation leads in turn to the 
inhibition of PKCζ responsible for the glucose transporter 4 (GLUT4) translocation, 
impairing insulin-induced glucose uptake. 
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To better address the effects of PED/PEA-15 over-expression on glucose 
tolerance a transgenic mouse has been generated, ubiquitously over-expressing 
Ped/Pea-15 gene. This mouse model exhibits mildly elevated random-fed 
blood glucose levels and becomes hyperglycemic after glucose loading, 
indicating that increased expression of this gene is sufficient to impair glucose 
tolerance (Vigliotta et al, 2004). Indeed, Ped/Pea-15 transgenic mice are much 
more insulin resistant than their nontransgenic littermates. The transgenic mice 
were consistently markedly hyperinsulinemic in the basal state and exhibited 
increased free fatty acid levels in blood. The transgenic mice also show 
reduced insulin response to a glucose challenge, indicating that the 
overexpression of Ped/Pea-15 impairs insulin secretion in addition to insulin 
action (Vigliotta et al, 2004). 
Moreover, to clarify the role of PED/PEA-15 in the glucose-regulated insulin 
secretion, it has been generated the transgenic mice over-expressing Ped/Pea-
15 selectively in β-cells. This animal model shows impaired glucose tolerance 
and reduced insulin secretion in response to hyperglycemia. This latter defect is 
comparable with that occurring in mice with ubiquitous overexpression, 
suggesting that β-cell overexpression of Ped/Pea-15 is sufficient to impair 
glucose tolerance in mice (Miele et al, 2007). Additional studies in Ped/Pea-15 
null mice revealed that the ablation of even a single copy of the gene is able to 
increase the insulin sensitivity (unpublished data). 
All these findings suggest that PED/PEA-15 has an important role in the 
control of insulin sensitivity and therefore its abnormalities provide a strong 
contribution to insulin resistance.  
Interestingly, it has been demonstrated that increased levels of PED/PEA-15 
also occur in euglycaemic subjects with diabetic first-degree relatives (FDR) 
respect to euglycaemic subjects with no family history of diabetes (Valentino 
et al, 2006). In addition, in nondiabetic offspring of type 2 diabetics from the 
European Network on Functional Genomics of Type 2 Diabetes (EUGENE2) 
cohort, PED/PEA-15 expression levels strongly correlate with insulin 
resistance (Valentino et al, 2006). 
As outlined above, in vitro and in vivo studies have clearly demonstrated the 
close relationship between Ped/Pea-15 over-expression and the impaired 
insulin action and secretion. However, the mechanisms through which this 
alteration in gene expression occurs are not fully elucidated. 
1.4.3 Ped/Pea-15 transcriptional regulation 
First evidence suggested that overexpression of Ped/Pea-15 in the diabetics 
may be caused by transcriptional abnormalities since no mutations were 
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detected by denaturing gradient gel electrophoresis (DGGE) in the coding 
region of the gene in 23 type 2 diabetic individuals analyzed (Condorelli et al, 
1998). 
To get further insight in Ped/Pea-15 transcriptional regulation, its promoter 
has been characterized, obtaining evidence that the balance between Chicken 
Ovalbumin Upstream Promoter Transcription Factor II (COUP-TFII) and 
Hepatocyte Nuclear Factor 4α (HNF-4α) could regulate, at least in part, its 
transcription acting as positive and negative regulators, respectively (Ungaro et 
al, 2008). In addition, both these factors are involved in the control of glucose 
homeostasis (Hayhurst et al, 2001; Pereira et al, 2000; Xanthopoulos et al, 
1991). Thus, abnormalities in their balance might have important consequences 
on glucose tolerance. Nevertheless, polymorphisms in their consensus binding 
sequence may affect Ped/Pea-15 expression, thereby increasing the 
susceptibility to type 2 diabetes. Further studies revealed that HNF-4α 
represses Ped/Pea-15 expression by triggering Silencing Mediator of Retinoic 
acid and Thyroid hormone receptor (SMRT) recruitment to the gene promoter 
and thereby, leading to histone deacetylation-associated remodelling of 
chromatin (Ungaro et al, 2010). 
More recently, it has been demonstrated that Peroxisome Proliferator-
Activated Receptor-γ (PPARγ) represses transcription of the Ped/Pea-15 gene, 
identifying it as a novel downstream target of a major PPARγ-regulated 
inflammatory network (Ungaro et al, 2012). In this context, it is well known 
that thiazolidinediones markedly improves insulin sensitivity in type 2 diabetic 
patients acting through peroxisome proliferator-activated receptor-γ (PPARγ) 
mediated mechanisms. Therefore, Ped/Pea-15 repression may contribute to 
thiazolidinediones action on glucose disposal. In addition, further results 
indicate that PPARγ regulates Ped/Pea-15 transcription by inhibiting c-JUN 
binding at its promoter (Ungaro et al, 2012). Accordingly, JNK/AP1 network 
together with NF-KB pathway are activated in classical insulin target tissues as 
a consequence of the chronic low grade inflammation, typical of both obesity 
and type 2 diabetes. (Bandyopadhyay et al, 2005; Itani et al, 2002; Osborn & 
Olefsky, 2012). 
However, whether the overexpression occurring in type 2 diabetic individuals 
is determined exclusively by genetic mechanisms and/or whether non genetic 
mechanisms may also contribute are issues that still remain to be established. 
Elucidating how the Ped/Pea-15 gene is regulated could generate further 
insight into the molecular bases of diabetes as well as novel translational 
perspectives. 
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2. AIMS OF THE STUDY 
Type 2 diabetes (T2D) is a metabolic disorder resulting from the complex 
interaction between genetic and environmental factors. It is a growing health 
problem worldwide and genetic models to explain its epidemic are inadequate 
because its increase has been too rapid to allow for the appearance of new 
mutant genes. In addition, increasing evidence show that environmental cues, 
such as fat-enriched diet, strongly contribute to development and progression 
of multifactorial disease, by altering gene expression through epigenetic 
modifications. 
Ped/Pea-15 gene is widely expressed in different tissues and highly 
conserved among mammals. It has emerged as an important regulator of insulin 
sensitivity. Indeed, Ped/Pea-15 is overexpressed in skeletal muscle and adipose 
tissues of type 2 diabetic individuals, as well as in white blood cells from non 
diabetic individuals with a strong family history of type 2 diabetes. 
However, whether the overexpression of Ped/Pea-15 gene is determined 
exclusively by genetic mechanisms and/or whether non genetic mechanisms 
may also contribute are issues that still remain to be established. 
Based on this knowledge, the aim of this work is to clarify whether and how 
external stimuli, such as the administration of a high fat diet, could impact on 
Ped/Pea-15 expression in insulin target tissues and whether chromatin 
remodelling and epigenetic modifications can play a role in the regulation of 
this candidate gene.  
The knowledge about the molecular mechanisms linking environmental factors 
and type 2 diabetes are still limited, so far. Therefore addressing this issue will 
provide some insights into epigenetic mechanisms associated with type 2 
diabetes. 
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3. MATERIALS AND METHODS 
3.1 Animal study 
Male C57Bl6/J mice were hosted at the common facility of the University of 
Naples Medical School. They were housed 5 per cage under the conditions of 
constant temperature (22°C), a light/dark cycle of 12 h with free access to food 
and water. Diet protocol started when mice where 7-week-old. For high fat diet 
(HFD) treatment, mice were fed a high fat diet with ~ 60 cal % fat or a 
standard diet with ~ 10 cal % fat (Research Diets, New Brunswick, NJ) for 22 
weeks. 
All the experiments performed on mice were conducted in accordance with 
the Principles of Laboratory Care. 
3.2 Glucose Tolerance Test (GTT) 
The test was performed at the beginning and at the end of the diet protocol. 
Mice were fasted overnight and then injected with 2g/kg body weight of 
glucose. Blood samples were taken from mice tail and glycaemia was analyzed 
by using a glucose analyzer (LifeScan). Glucose levels were determined at the 
following time points: 0, 15, 30, 45, 60, 90, 120 min after glucose injection.  
3.3 Insulin Tolerance Test (ITT) 
The test was performed at the beginning and at the end of the diet protocol. 
Insulin sensitivity was assessed on 5 hr starved mice and then injected with 
0,75 U/kg body weight of insulin. Blood samples were taken from mice tail 
and glycaemia was analyzed by using a glucose analyzer (LifeScan). Glucose 
levels were determined at the following time points: 0, 15, 30, 45, 60, 90, 120 
min after insulin injection. 
3.4 Glucose-Stimulated Insulin Secretion (GSIS) 
The test was performed upon 22 weeks of diet protocol on overnight fasted 
mice. Animals were intraperitoneally injected with 3g/kg body weight of 
glucose. In parallel, blood samples were taken from mice tail, to assess 
glycaemia, and from orbital sinus in order to collect large volumes of blood to 
further measure serum insulin. Animals received topical anesthetic during this 
procedure (tetracaine ophthalmic drops). Blood samples were collected at 0, 3 
30 min after glucose injection. Blood samples were centrifuged at 1500 rpm for 
20 min at room temperature and serum collected. Insulin levels were measured 
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with radioimmunoassay (RIA) kit (#RI-13K, Millipore), according to the 
manufacturer’s protocol. 
3.5 Biochemical parameters 
In overnight fasted mice, analyses of serum triglycerides, total cholesterol, 
HDL, LDL, were done by using Horiba ABX Pentra400 Chemistry Analyzer 
(HORIBA ABX, Montpellier, France). 
3.6 Western Blot Analysis 
Tissues were weighed and total proteins were extracted in JS buffer (Hepes 1 
M pH 7.5, NaCl 5 M, glycerol 100%, Triton x-100 1%, MgCl2 1 M, EGTA 
0,1M), supplemented with the Complete Protease Inhibitor Mixture Tablets 
(Roche Applied Science). After lysates clarification, protein concentration was 
determined using Bradford assay (Bio-Rad). Protein extracts (200 µg skeletal 
muscle- 50 µg liver- 100 µg adipose tissue) were resolved by SDS-PAGE and 
blotted on nitrocellulose membranes (Millipore, Billerica, MA). Nonspecific 
binding was blocked with 5% nonfat milk for 1 h at the room temperature. 
Bands were visualized by reacting with specific antibodies which were 
revealed by chemio-luminescence (Amersham, Biosciences). The following 
antibodies were used: rabbit anti-PEA-15 (#2780 Cell Signaling) and mouse 
anti-α-tubulin (T5168 Sigma), as loading control. 
3.7 Real time PCR 
70mg of tissue were weighed and total RNA was isolated using Trizol 
reagent (Aurogene), according to the manufacturer’s protocol. The cDNA 
synthesis was generated from 1 µg of total RNA by using Superscript II 
(Invitrogen, Life Technologies) in a 20 µl reaction volume. After cDNA 
synthesis, Real time PCR was performed on CFX96 (Biorad) in a final volume 
of 10 µl containing 20 ng of cDNA, 5 µl of iTaq Universal SYBR Green 
Supermix (Biorad) and specific forward and reverse primers (Sigma). The 
sequences of the primers used are listed in Table 1. The Gapdh gene was used 
as internal control and the results of Real time analysis are expressed as the 
ratio between the copy number variation (CNV) of Ped/Pea-15 and that of the 
reference gene. 
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Table 1 primers sequences used for Real time PCR 
GENE NAME PRIMER SEQUENCES (5’-3’) 
PED/PEA-15 Forw: ggcagtgcctggtttagcttc 
Rev: tcagagggctgccggataatg 
GAPDH Forw: aaggcgggggcccacttgaa 
Rev: tgggtggcagtgatggcatgg 
For the analysis of Ped/Pea-15 mRNA levels, target gene expression was measured 
using the absolute standard curve method for Real time PCR. GAPDH, was used as 
internal control. Forw: forward primer, Rev: reverse primer 
3.7.1 Cloning of the real-time PCR amplification products of Ped/Pea-15 
and Gapdh for copy number analysis 
For copy number analysis, the real time PCR amplification products for 
Ped/Pea-15 and Gapdh were cloned into the pGEM-T easy vector (Promega, 
Madison, WI), according to the manufacturer’s protocol. Calibration curves 
were made from serial 10-fold dilutions of plasmid DNAs, from 1.0 ng/µl to 
1.0 × 10-8 ng/µl. The reproducibility of the calibration curves was tested 
according to the slopes and the correlation coefficients. The mean slopes of the 
calibration curves for the two genes were similar, -3,3 for Ped/Pea-15 and -3,1 
for Gapdh, where a slope of -3,3 ± 10% reflects an efficiency of 100% of the 
PCR, and the mean correlation coefficient for both curves was 0,99. The copy 
number of the genes was calculated using the Ct values of the vector and 
calculating the vector copy number according to the formula (Dhanasekaran et 
al, 2010; Yuan et al, 2006): 
Number of copies = (amount (ng) ∗ 6.022×1023)/ (length (bp) ∗ 1.0×109 ∗ 650) 
This formula takes into account 6.022 × 1023 (molecules/mole) that is the 
Avogadro’s number and 660 Da that is the average weight of a single base pair 
(http://cels.uri.edu/gsc/cndna.html). 
3.8 Formaldehyde-Assisted Isolation of Regulatory Elements (FAIRE) 
Frozen tissues were pulverized into a coarse powder in liquid nitrogen, cross-
linked in formaldehyde 1% for 10 min and then quenched with the addition of 
glycine 125 mM. Following PBS washing, tissues were lysed in ice-cold 
FAIRE lysis buffer (10 mM Tris-HCl pH 8.0, 2% vol/vol Triton X-100, 1% 
SDS, 100 mM NaCl, 1 mM EDTA) by using metal beads. The cross-linked 
chromatin was sheared by sonication (six 30-s cycles with 1-s bursts followed 
by 0.5 s of rest at 30% amplitude) in order to achieve a range of about 150–750 
bp with an average fragment length around 300–400 bp. Lysates were clarified 
by centrifugation and a 100-µl aliquot was removed to check efficiency of 
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sonication and to prepare INPUT DNA, used as loading control. The remaining 
lysate was used to obtain FAIRE DNA. To get INPUT DNA, lysates were 
treated with DNase-free RNaseA and proteinase K, before phenol/chloroform 
extraction. Efficiency of sonication was evaluated by running 500 ng INPUT 
DNA on a 1% (wt/vol) agarose gel and stained with ethidium bromide. FAIRE 
DNA was prepared, instead, by direct phenol/chloroform extraction and then 
proteinase K was added to reverse any DNA-DNA cross-links. Both, INPUT 
and FAIRE DNA were analyzed by semiquantitative PCR, resolved by 2% 
agarose gel electrophoresis and analyzed by densitometry using the ImageJ 
software (National Institutes of Health). The sequences of the primers used are 
listed in Table 2. FAIRE DNA was normalized to INPUT DNA. 
Table 2 Primers sequences used to analyze Ped/Pea-15 promoter 
Ped/Pea-15 PROMOTER REGION PRIMER SEQUENCES (5’-3’) 
mPED_A Forw: ggaggggtcatgtaaaagca 
Rev: ggcaggattattcccatcttc 
mPED_B Forw: ggctcaggtgggagtaaaca 
Rev: ttctgtcgctttccctaagaa 
mPED_C Forw: tccacagtcaaatccaggaag 
Rev: tgaggcagagcaaaacacag 
mPED_D Forw: ctgtgttttgctctgcctca 
Rev: cctgagaacggcttcaatgt 
mPED_E Forw: acattgaagccgttctcagg 
Rev: cacacccccacacactatga 
mPED_F Forw: tcatagtgtgtgggggtgtg 
Rev: ggaaggcagatcaatttgga 
mPED_G Forw: tccaaattgatctgccttcc 
Rev: gttcctaagcagcgtctg 
PCR primers were designed to produce a series of adjacent partially overlapping PCR 
products spanning nucleotides -2000 to +165 (distance are relative to transcription 
start site) of Ped/Pea-15 promoter. A: from -2000 to -1650; B: from -1771 to -1475; C: 
from -1499 to -1150; D: from -1181 to -803; E: from -823 to -514; F: from -534 to -
226; G: from –245 to +162; Forw, forward primer; Rev, reverse primer. 
3.9 Micrococcal Nuclease assay (MNase) 
Frozen tissues were minced, washed with ice-cold PBS and lysed in ice-cold 
lysis buffer (10mM Tris pH 7.5, 10mM NaCl, 3mM MgCl2, 0.5% NP-40, 
0.15mM spermine, 0.5mM spermidine) by using metal beads. Nuclei were 
centrifuged at 2000 rpm for 5 min at 4°C and resuspended in the MNase 
digestion buffer (10mM Tris-HCl pH 7.4, 15mM NaCl, 60mM KCl, 0.15mM 
spermine, 0.5mM spermidine) and the final Ca2+ concentration adjusted to 
1mM with CaCl2. 0,1 U MNase was added and the reaction mixture was 
incubated at 37°C for 5 min. An aliquot was removed, as undigested DNA 
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control. Thus, the reaction was stopped by adding MNase Stop Buffer (20mM 
EDTA, 20mM EGTA, 0.4% SDS, 0.5mg/mL Proteinase K) and the mixture 
incubated at 65°C overnight. Both digested and undigested DNA were obtained 
by direct phenol/chloroform extraction and analyzed by semiquantitative PCR, 
resolved by 2% agarose gel electrophoresis and analyzed by densitometry 
using the ImageJ software (National Institutes of Health). MNase digested 
DNA was normalized to undigested DNA. 
3.10 Chromatin Immunoprecipitation assay (ChIP) 
Tissues were minced and protein-DNA cross-linked in presence of 1% 
formaldehyde for 15 min. The cross-linking reaction was stopped by the 
addition of glycine 125mM. Tissues were lysed and sonicated to achieve 
chromatin fragments ranging between 500 and 1000 bp in size. The lysates 
were incubated at 4°C overnight with appropriated antibodies: anti.acetyl-
Histone H4 (#06-866, Millipore), anti-dimethyl-Histone H3 (Lys9) (#17-648, 
Millipore), anti-dimethyl-Histone H3 (Lys4) (#07-030, Millipore), anti histone 
H3 (#2650, Cell Signaling), anti Histone H3K4me3 (#39915, Active Motif), 
anti Histone H3K4me1 (#39635, Active Motif), anti-Histone H3K27ac 
(#39685, Active Motif), anti RNA Pol II (MMS-134R, Covance), anti p300 
(#N-15, S. Cruz Biotechnology), anti SET7/9 (#5131-1, Epitomics); normal 
rabbit serum was used as negative control (#17-684 Millipore). Thus, 
chromatin-antibody complexes were isolated using protein G/salmon sperm 
DNA (Millipore, Billerica, MA). Immunoprecipitates and INPUT controls 
(aliquot separated before immunoprecipitation) were washed and then eluted 
by freshly prepared 1% SDS, 0.1M NaHCO3 buffer. After reversion cross-
linking, DNA was purified by the QIAquick PCR purification kit (Qiagen, 
Hilden, Germany) followed by PCR amplification. PCR products were 
resolved by 2% agarose gel electrophoresis, revealed by ethidium bromide 
staining. Bands were analyzed by densitometry using the ImageJ software 
(National Institutes of Health); immunoprecipitated DNA signals were 
normalized to relative input samples and corrected to negative control. 
3.11 Statistical analysis 
Data are expressed as mean ± SEM. Statistical significance of the differences 
between groups was determined by two-tailed unpaired Student’s t test with the 
GraphPad prism software (*p < 0.05, **p < 0.01, ***p < 0.001). 
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4. RESULTS AND DISCUSSION 
4.1 Animal study design 
It has been well established that the link between obesity and type 2 diabetes 
is not restricted to humans. When provided to various animal species, high fat 
diet leads to obesity and induces disease signs that model human type 2 
diabetes. Moreover, diet-induced obesity (DIO) in the mouse, in the absence of 
mutation of selected genes, provide a powerful tool for identifying epigenetic 
and environmental mechanisms potentially involved.  
C57Bl6/J is a well established models for diet-induced obesity; this strain 
develops severe obesity, hyperglycemia and insulin resistance if weaned onto 
high fat diet, and therefore it was used for this study. 
Animals were acclimated for 3-weeks before experiments and diet protocol 
started when mice were 7 week-old. Briefly, male mice were used to avoid sex 
hormones influences and were divided into two groups: 8 mice were fed with a 
standard diet (10% animal fat) and 8 mice were put on diet-induced obesity 
regimen (60% animal fat). After 22 weeks of diet protocol, mice were 
sacrificed and tissues collected (Figure 6). 
 
 Figure 6 Animal study design for diet
used for diet-induced obesity 
were fed a standad diet (STD); 8 animals 
weeks of diet protocol, mice were sacrificed and tissues collected.
4.2 Metabolic characteristics of 
Body weight and food intake were
duration. The body weight started to differ between 
high fat diet mice (HFD
vs 28 ± 0,3 g HFD p
weight of STD and HFD mice at the beginning and at 
HFD mice significantly increased their body weight after 22 weeks of feeding 
(T0 24,2 ± 0,4 g vs T
displayed only a mild body weight increase
g; p-value < 0.05). Concomitantly, food intake was evaluated; food intake was 
not affected between the two 
g/mouse/day vs HFD 2
the calorie intakes were affected by type of diet (STD 97 
kCal/mouse/week vs 
 
-induced obesity. C57Bl6/J mal
protocol. Mice were divided into two groups:8 animals 
were fed a high fat diet (HFD). After 22 
 
standard and high fat mice 
 weekly evaluated during diet protocol 
standard mice 
) already after two weeks of feeding (25,5 ± 0,4 g 
-value=2x10-5). Figure 7a shows the difference in body 
the end of diet protocol
22 40,9 ± 1,0 g; p-value < 0.001). At variance
 (T0 24,5 ± 0,4 g vs T
experimental groups (STD 
0,3 ± 0,3 g/mouse/week) (data not shown)
HFD 189 ± 15,4 kCal/mouse/week; p-value < 0.01
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Thus, I characterized the glucose homeostasis of this mouse model, analyzing 
the blood glucose levels and the glucose tolerance. Fasting blood glucose was 
markedly increased in HFD group but not in STD mice (Figure 7b). In 
addition, during a glucose tolerance test (GTT), glucose loading (2g/kg) 
rendered HFD mice significantly more hyperglycemic during the following 
120 min compared to the STD mice, revealing a strong impairment of glucose 
tolerance after 22 weeks of feeding (Figure 7c).  
Later, I also performed an insulin tolerance test (ITT); after intraperitoneal 
insulin injection (0.75mU/g) HFD mice displayed reduced insulin sensitivity 
compared to the control mice (Figure 7d). Therefore, upon 22 weeks of high fat 
diet administration mice become both glucose intolerant and insulin resistant. 
Moreover, I performed a glucose-stimulated insulin secretion (GSIS) test to 
evaluate the appropriate secretion of insulin from pancreatic β-cells (Figure 
7e). It is well known that glucose induces insulin secretion in a biphasic 
pattern: the first phase, which culminates after 5-6 minutes after stimulation, 
and the second phase, characterized by a gradual increase over 60 min (Seino 
et al, 2011). Loss of first-phase secretion and reduced second-phase secretion 
are characteristic features of type 2 diabetes mellitus (T2DM). Thus, the 
analysis of GSIS revealed that HFD mice are hyperinsulinemic in the basal 
state compared to control mice; indeed, both the first and the second fases are 
absent upon glucose stimulation. 
Furthermore, as shown in Table 3, over 22 weeks of feeding HFD mice have 
significantly elevated total cholesterol, LDL and HDL; the increase of this last 
parameter is probably due to a compensatory effect. At variance, triglycerides 
levels did not differ between STD and HFD mice. The unchanged triglycerides 
levels are in accordance with data already published in literature. Indeed, 
hypertriglyceridemia, even though is closely associated with insulin resistance, 
is not induced in mice upon HFD administration (Buhman et al, 2000; Kirk et 
al, 1995). 
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Figure 7 Effect of HFD on (a) Body weight, (b) fasting blood glucose, (c) glucose 
tolerance, (d) insulin sensitivity, (e) glucose stimulated insulin secretion. Data 
shown are mean ± SEM. Significant differences are indicated. *p<0.05, **p<0.01, 
*p<0.001. STD, standard diet; HFD, high fat diet; AUC, area under the curve. 
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Table 3 Biochemical parameters of C57Bl6/J mice fed with STD or HFD 
weeks 0 22 
 STD HFD STD HFD 
CHOL 
(mg/dL) 95,2 ± 7,2 102,2 ± 8,3 97,7 ± 7,9 204,1 ± 8,9***
,§§§ 
TG 
(mg/dL) 100,3 ± 9,7 99,7 ± 12,9 99,6 ± 11,5 116,5 ± 10,0 
HDL  
(mg/dL) 54,8 ± 5,9 60,8 ± 5,02 54,2 ±  4,3 87,2 ± 2,4***
,§§ 
LDL  
(mg/dL) 7,7 ± 1,3 6,6 ± 1,7 8,4 ±  0,9 17,9 ± 1,2***
,§§§ 
Data are mean ± SEM of 8 animals/group. Total Cholesterol (CHOL), serum 
triglyceride (TG), serum HDL and LDL were determined in overnight fasted mice on 
high fat diet (HFD) or standard diet (STD) at the beginning and after 22 weeks of 
feeding. HFD vs STD at 22 weeks: ***p<0.001; HFD at 22 weeks vs HFD at 0 week: 
§§§p<0.001. 
4.3 Effect of high fat diet on Ped/Pea-15 levels in insulin target tissues 
 
As I mentioned before, Phosphoprotein Enriched in Diabetes/ 
Phosphoprotein Enriched in Astrocytes (Ped/Pea-15) gene is commonly over-
expressed in type 2 diabetic individuals. In this context, I investigated whether 
Ped/Pea-15 expression could be affected by external cues, in particular by a 
high fat diet administration.  
Therefore, by immunoblotting analysis I compared the PED/PEA-15 protein 
levels in liver, skeletal muscle and visceral adipose tissues of mice fed with 
standard or high fat diet for 22 weeks. The results show that HFD mice have 
higher PED/PEA-15 protein levels than STD mice both in skeletal muscle and 
adipose tissues but not in the liver (Figure 8).  
 Figure 8 Ped/Pea-15 protein expression i
Western blot analysis of PED/PEA
muscle (200µg.), visceral adipose tissue (
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PAGE followed by immunoblotting with PED/PEA
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liver. STD, standard diet; HFD, high fat diet. 
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expression by performing 
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that Ped/Pea-15 expression levels are higher in the liver than in skeletal 
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post-transcriptional regul
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levels and this regulation seems to be 
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. b) Densitometric analyses of the data. Bars represent
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Asterisks denote statistically significant 
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 regulation, I evaluated Ped/Pea
Real-time PCR (Figure 9). The results obtained
analysis. Indeed, the skeletal muscle and 
-fold and more than two-fold increase 
ation could probably occur.  
affects Ped/Pea-15 expression at transcriptional 
regulated in a tissue-specific manner.
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 Therefore, for the first time it has been demonstrated that 
modulated by environmental cues.
 
Figure 9 Ped/Pea-15 mRNA expression levels in insulin target tissues.
mRNA levels were measured performing absolute 
PCR analysis. Data are shown as copy number variation
normalized on CNV of a reference gene. 
S.M., skeletal muscle, V.A.T., visceral adipose tissue, L., liver; STD, standard diet; 
HFD, high fat diet. 
p<0.01;***, p<0.001). 
4.4 Effect of high fat diet on chromatin remodel
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Figure 10 Chromatin remode
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4.5 Effect of high fat diet on nucleosomes positioning at the Ped/Pea-15 
promoter 
To clarify whether the increase in the FAIRE signals observed at specific 
Ped/Pea-15 regions were a direct consequence of nucleosomes removal, I 
performed Micrococcal Nuclease (MNase) assays. 
Many studies indicated that nucleosome organization is somewhat 
nonrandom and that some regions of the genome are more likely to contain 
nucleosomes than others. Thus, nucleosomes positioning has clear implications 
for gene regulation. 
After nuclei isolation and MNase digestion, nucleosome-protected DNA was 
evaluated by qPCR and data are represented as the percentage of the loss of 
amplification following MNase digestion. As shown in Figure 11, the amount 
of nucleosome-bound DNA in STD and HFD mice, both in the skeletal muscle 
and in the liver, is lower around the transcription start site (region G) compared 
to the upstream fragments analyzed (regions A-B), as expected. Indeed, open 
promoters regulating the expression of constitutive genes, generally lack 
nucleosomes at transcription start site allowing access to transcription factors. 
Interestingly, in the skeletal muscle of HFD mice regions that demonstrated 
increased FAIRE signals (regions A-B) showed increased MNase sensitivity, 
reported as reduced nucleosome-bound DNA, thus suggesting a more open 
chromatin compared to their control mice (Figure 11). 
At variance, in the liver high fat diet did not affect chromatin structure at the 
same regions, confirming FAIRE results previously obtained (Figure 11). 
Moreover, since the increased MNase sensitivity observed in the regions A and 
B of HFD mice skeletal muscle is not so strong as that obtained in region G, it 
could reflect a more active chromatin conformation rather than nucleosome 
depleted regions.  
 
 
 
 
 
 Figure 11 Micrococcal Nuclease (MNase) assays
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 Figure 12 Nucleosome occupancy at 
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4.6 Effect of high fat diet on histone modification at Ped/Pea
promoter 
Gene transcription and activation are dynamic processes involv
conversion of more closed chromatin into transcription factor
euchromatin (Berger, 2007
modifications. Their presence or absence may create or disrupt chromatin 
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and H4 are the most 
(Grunstein, 1997; Lachner & Jenuwein, 2002
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2009; Wheatley et al, 2011
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To test this hypothesis, I evaluated the levels of histone 4 acetylation
and di-methylation of lysine 4 o
gene activation, and di
marker of gene repression. These histone marks were 
promoter region covering 2000 
(TSS) of Ped/Pea-15
analysis show that both AcH4 and H3K4me2 are increased in the skeletal 
muscle tissue but not in the liver 
In contrast, H3K9me2 levels were 
between the two groups of animals were detected
Ped/Pea-15 promoter. Relative quantification 
y at specific Ped/Pea-15 promoter, in skeletal muscle and 
normalized to Input control and 
andard diet; HFD, high fat diet;
-1771 to -1475; G: from –245 to +162 (distance are relative to 
. 
). A key role in these processes is played by histone 
those on
studied and involved in the regulation of gene expression 
). Moreover, regulation of histone 
 (Wellen et al, 
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Ped/Pea-15 expression in the 
 of HFD mice may be the results of specific histone 
 gene 
n histone 3 (H3K4me2) that commonly dictate 
-methylation of lysine 9 on histone 3 (H3K9me2)
globally evaluated
base pairs upstream the transcription start site 
 gene (Figure 13). Chromatin immunoprecipitation 
upon 22 weeks of high fat diet administration.
low in both tissues and no differences 
. These results suggest that 
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 increasing levels of 
accompanied by an increase of 
In contrast, in the liver, in which the gene does not increase upon high fat diet 
administration, any increase is detected. All together these data
possible correlation between 
gene expression. 
Figure 13 High fat diet increases histo
methylation at PED/PEA
promoter region DNA immuno
H3K9me2 antibodies, in skeletal muscl
right panels, respectively
amplification with primers spanning the 
transcription start site. Results are expressed as enri
corrected for IgG control levels. 
acetyl histone H4; H3K4me2, 
lysine 9 on histone H3;
statistically significant differences (**, p<0.01;***, p<0.001).
Thus, to get further insight into the functional role of AcH4 and H3K4me2
the regulation of 
immunoprecipitation-
at specific regions of 
abundance of histone modifications, 
increased in skeletal muscle of HFD mice 
particular, acetylation increases in proximity of the transcription start site
interestingly, in the region 
(Figure 14b). In contrast, acetylation levels in liver of HFD mice slight increase 
nearby the transcription start site and never reach the levels recorded in skeletal 
muscle. Moreover, any increase of AcH4 have been detected around 
(regions A-B) in the liver upon
parallel, H3K4me2 levels in
fat diet administration (Figure 1
strong increase as acetylation. Finally, no differences were observed regarding 
Ped/Pea-15 gene in skeletal muscle tissue 
euchromatin histone marks. 
high fat diet induced histone modifications and 
ne H4 acetylation and lysine 4 di
-15 promoter. Relative quantification of 
precipitated with anti -AcH4, -H3K4me2 
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). Chromatin immunoprecipitation was followed by PCR 
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chment relative to input (%) and 
Data are means ± SEM of 8 animals/group. AcH4
di-methyl lysine 4 on histone H3; H3K9me2, 
 STD, standard diet; HFD, high fat diet. Asterisks denote 
  
Ped/Pea-15 expression, I performed a chromatin 
walking to identify the enrichment of these histone marks
Ped/Pea-15 promoter (Figure 14). Comparing relative 
histone 4 acetylation 
compared to control 
from -2000 to -1475 it shows the highest levels 
 high fat diet administration (Figure 1
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H3K9me2 levels between the two experimental groups, in both tissues, 
suggesting that this histone mark does probably not play any role in the 
regulation of PED/PEA-15 gene (Figure 14 f-g).  
 
 
 
 
 Figure 14 Relative abundance of histone modifications on PED/PEA
promoter. a) Schematic representation o
regions analyzed by Chromatin immunoprecipitation assays and amplified by seven 
different primers pairs 
Ped/PEA-15 transcription start site.
g) Plots show the AcH4, H3K4me2 and H3K9me2 levels on Ped/Pea
skeletal muscle (left panels) and in liver (right panels). 
enrichment relative to input (%) and corrected for 
± SEM of 8 animals/ group. STD, standard diet; HFD, high fat diet. Asterisks denote 
statistically significant differences (*, p<0.05; **, p<0.01;***, p<0.001).
f Ped/Pea-15 promoter; black bars indicate 
(listed in Table 2) spanning the 2000 base pairs upstream the 
 distances are relative to transcription start site
-15 promoter in 
Results are expressed as 
IgG control levels. Data are means 
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4.7 Tissue-specific effect of high fat diet on a distal Ped/pea-15 promoter 
region 
It is now clear that non-coding sequences play a key role in regulating gene 
expression. Moreover, transcription can be regulated by multiple and different 
types of cis-regulatory elements that can also act over distance. Distant 
regulatory elements, such as enhancers, have the ability to regulate tissue-
specific gene expression in an orientation dependent manner (Jin et al, 2011). 
With respect to enhancer identification, a particularly relevant insight was the 
identification of specific histone methylation signatures. In contrast to 
promoters, which are marked by trimethylation of histone H3 at lysine residue 
4 (H3K4me3), active enhancers are characterized by monomethylation at the 
same position (H3K4me1) (Visel et al, 2009). In addition, based on the 
presence/absence of histone acetylation they can be classified into active or 
poised enhancers, respectively (Creyghton et al, 2010; Rada-Iglesias et al, 
2011). Importantly, these predicted enhancers can be also frequently associated 
with co-activators like p300 or TRAP220. 
Based on this knowledge, I wondered whether the distal promoter region 
analyzed could act as a distal regulatory element. Therefore, I performed 
chromatin immunoprecipitation assays in order to evaluate the levels of 
monomethylated lysine 4 at histone H3 (H3K4me1). As shown in Figure 15a, 
H3K4me1 levels strongly increase upon high fat diet administration in skeletal 
muscle tissue but not in the liver. Moreover, mice fed standard diet show 
higher levels of H3K4me1 in muscle than in liver (p<0.05), suggesting  that 
this region could have a role in skeletal muscle but not in the liver in regulating 
Ped/Pea-15 expression.  
As discussed above, distal regulatory regions can be classified into “poised” 
or “active” based on their acetylation levels. In particular, poised enhancers are 
associated with basal levels of H3K4me1 without H3K27Ac. Thus, upon 
appropriate stimulations they can switch from poised to active enhancers, 
acquiring H3K27Ac (Ostuni et al, 2013). Therefore, I evaluated H3K27Ac 
levels and, as shown in Figure 15a, the monomethylation of lysine 4 is 
accompanied by the acetylation at lysine residue 27 in the skeletal muscle of 
high fed diet mice, whereas the same region in the liver does not acquire this 
feature. 
Then, I also evaluated the trimethylation levels at lysine residue 4 on histone 
H3 (Figure 15b). This histone mark is enriched at active promoter regions. 
Chromatin immunoprecipitation experiments revealed that H3K4me3 levels 
can be detected across PED/PEA-15 transcription start site both in muscle and 
in liver, indicating that the gene is transcribed in both tissues. Moreover, upon 
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high fat diet administration H3K4me3 levels result in a slight increase in the 
liver and in a much more consistent increase in skeletal muscle. Finally, I 
considered an additional feature known to be associated with promoters, that is 
RNA polymerase II. The recruitment of RNA polymerase II is detectable in the 
two experimental groups in skeletal muscle as well as in the liver. However, 
there is an increase in its recruitment only in the muscle upon high fat diet 
administration (Figure 15b).  
 
 
 
 
 
 
 
 
 
 
 
 Figure 15 Specific histone marks enrichment at selected 
regions. ChIP experiments were performed using antibodies against 
H3K27Ac, H3K4me3 and Pol II 
immunoprecipitation was followed by PCR amplification with primers for 
regions as indicated in the
graphs show H3K4me1 and H3K27Ac levels on distal promoter region
-1475). b). Bar graphs show
Ped/Pea
or nonspecific IgG antibodies
schematic representation of Ped/Pea-15 promoter
 
 H3K4me3 levels and Pol II recruitment across 
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-15 promoter 
H3K4me1, 
. Chromatin 
A, B and G 
 a) Bar 
(from -2000 to 
Ped/Pea-
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15 TSS (-246 to +162). Results are expressed as enrichment relative to input (%), 
corrected for IgG control levels and are means ± SEM of 8 animals/ group. H3K4me1, 
monomethylation of lysine 4 on histone H3; H3K27Ac, acetylation of lysine 27 on 
histone H3; H3K4me3, trimethylation of lysine 4 on histone H3; Pol II, Polymerase II; 
TSS, transcription start site. STD, standard diet; HFD, high fat diet. Asterisks denote 
statistically significant differences (*, p<0.05; **, p<0.01;***, p<0.001). 
Different classes of histone methyltransferase can mediate the H3K4me1: the 
SET-domain containing protein, the ASH-like protein and the MLL-proteins. It 
has been recently demonstrated that SET7/9 may regulate gene expression 
under hyperglycaemic/hyperinsulinemic conditions and it is involved in the 
development and in the progression of diabetic vascular complications. 
Thus, I wanted to determine whether SET7/9 is involved in the 
monomethylation of Ped/Pea-15 promoter. Therefore, I performed chromatin 
immunoprecipitation assay using antibody against SET7/9 followed by the 
amplification of regions that showed higher levels of H3K4me1(regions A-B) 
(Figure 16). As shown in figure 16a, SET7/9 binds Ped/Pea-15 promoter even 
though there is no further recruitment in the skeletal muscle tissue upon high 
fat diet administration. Although I observed an increase in histone H3K4 
monomethylation in the skeletal muscle, the binding of SET7/9 enzyme was 
not changed. This result could be explained in different ways; it is possible that 
high fat diet may alter its enzymatic activity rather than its amount at the 
selected promoter region. Moreover, SET7/9 is not the only histone 
methyltransferase that mediates this modification and thus it is possible that 
other enzymes take part to this process. Instead, in the liver low levels of 
H3K4me1 well correlate with low levels of SET7/9 at Ped/Pea-15 promoter, 
both in high fat diet and standard mice (Figure 16b). 
In addition, because distal regulatory elements can be associated with the 
histone acetyltransferase p300, I also tested its recruitment at Ped/Pea-15 
promoter region associated with high levels of acetylated H3K27 (Figure 16). 
Upon high fat diet administration, the binding of p300 in the skeletal muscle 
strongly increased compared to standard mice (Figure 16a). At variance, this 
increase was not observed in the liver (Figure 16b). 
 
 Figure 16 SET7/9 and p300 recruitment at the Ped/Pea
immunoprecipitation assays 
p300. ChIP-enriched samples were amplified by 
Ped/Pea15 promoter primers 
-1771 to -1475). Experiments were performed in skeletal muscle 
Bar graphs are means ± SEM of 8 animals/ group
relative to input (%), corrected for IgG control levels
fat diet. Asterisks denote
In the last years enhancer have attracted much attention due to their ability 
and critical role in regulating gene expression. Active enhancers may activate 
genes trough different mechanisms, such as dir
altering nuclear organization, changing chromatin structure. Thus, 
these data suggest that this distant region could be responsible of the tissue
specific Ped/Pea-15 up
the shape of the genome provided evidence that 
-15 promoter
were performed using antibodies against
semiquantitative PCR using specific 
amplifying regions A (from -2000 to -1650) and B
(a) and in liver 
 and are expressed as enrichment 
. STD, standard diet; HFD, high 
 statistically significant differences (**, p<0.01).
ect interaction with promoter, 
-regulation upon high fat diet administratio
distal regulatory DNA 
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sequences can control transcription over distance by physically contacting 
target genes via chromatin looping (Holwerda & de Laat, 2012). It would be a 
great challenge to demonstrate that this mechanism also occur on Ped/Pea-15 
promoter. Thereby run-on experiments aims at evaluating the physical contact 
between this distal region and the proximal promoter through chromatin 
conformation capture technique (3C). 
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5. CONCLUSIONS 
This work has identified the impact of the environment on the regulation of 
Ped/Pea-15 gene focusing on chromatin modification phenomena. The 
administration of a high fat diet in mice is able to affect Ped/Pea-15 expression 
in insulin target tissues, through transcriptional regulation. Indeed, its 
transcriptional levels increased in skeletal muscle and in visceral adipose tissue 
but not in the liver, thus suggesting potential tissue-specific mechanisms. 
Moreover, the increased expression was accompanied by a change of 
chromatin organization not due to a nucleosomes repositioning but to a change 
in histone modifications. Specifically, Ped/Pea-15 levels increase together with 
histone 4 acetylation and histone 3 dimethylation at lysine 4 on its promoter 
region. These two histone marks are associated with active chromatin and 
therefore may be involved in the regulation of Ped/Pea-15 mRNA expression. 
This study also provides new insight regarding the presence of a distal 
regulatory element switched from poised into active status upon high fat diet 
administration that can have an impact on chromatin organization and 
transcriptional activity of the gene. 
Since evidence linking specific environmental cues and metabolic disorders 
are still limited, elucidating the mechanisms through which environmental 
factors can alter metabolic homeostasis remain a challenge. 
Phosphoprotein Enriched in Diabetes/Phosphoprotein enriched in Astrocytes 
(PED/PEA-15) gene plays a crucial role in the regulation of insulin sensitivity, 
both in humans and in rodents. Indeed, the overexpression of this gene is a 
common feature of type 2 diabetic individuals. 
Therefore highlighting how environment impacts on its expression could be a 
good-model to understand more general epigenetic mechanisms by which 
nutrition interacts with the genome thereby influencing metabolic health. 
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Peroxisome Proliferator-activated Receptor-! Activation
Enhances Insulin-stimulated Glucose Disposal by Reducing
ped/pea-15 Gene Expression in Skeletal Muscle Cells
EVIDENCE FOR INVOLVEMENTOF ACTIVATOR PROTEIN-1*
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Background: PPAR!modulation of glucoregulatory response in skeletal muscle has been only partially elucidated.
Results: PPAR! inhibits the transcription of the diabetes-associated gene ped/pea-15 via AP-1.
Conclusion: ped/pea-15 is downstream of a PPAR!-regulated inflammatory network.
Significance: These studies further elucidate the gene network responsible for inflammation-induced insulin resistance.
Thegenenetworkresponsible for inflammation-induced insulin
resistance remains enigmatic. In this study, we show that, in L6
cells, rosiglitazone- aswell as pioglitazone-dependent activationof
peroxisome proliferator-activated receptor-! (PPAR!) represses
transcription of the ped/pea-15 gene, whose increased activity
impairs glucose tolerance in mice and humans. Rosiglitazone
enhanced insulin-inducedglucoseuptake inL6cells expressing the
endogenous ped/pea-15 gene but not in cells expressing ped/
pea-15 under the control of an exogenous promoter. The ability of
PPAR! to affectped/pea-15 expressionwas also lost in cells and in
C57BL/6J transgenic mice expressing ped/pea-15 under the con-
trol of an exogenous promoter, suggesting thatped/pea-15 repres-
sion may contribute to rosiglitazone action on glucose disposal.
Indeed, high fat dietmice showed insulin resistance and increased
ped/pea-15 levels, although these effectswere reducedby rosiglita-
zone treatment.Both supershift andChIPassays revealed thepres-
ence of the AP-1 component c-JUN at the PED/PEA-15 promoter
upon 12-O-tetradecanoylphorbol-13-acetate stimulation of the
cells. In these experiments, rosiglitazone treatment reduced c-JUN
presence at the PED/PEA-15 promoter. This effect was not associ-
atedwith a decrease in c-JUNexpression. In addition, c-jun silenc-
ing in L6 cells lowered ped/pea-15 expression and caused nonre-
sponsiveness to rosiglitazone, although c-jun overexpression
enhanced thebinding to theped/pea-15promoter andblocked the
rosiglitazone effect. These results indicate that PPAR! regulates
ped/pea-15 transcription by inhibiting c-JUN binding at the ped/
pea-15 promoter. Thus, ped/pea-15 is downstream of a major
PPAR!-regulated inflammatory network. Repression of ped/
pea-15 transcriptionmight contribute to the PPAR! regulation of
muscle sensitivity to insulin.
Peroxisome proliferator-activated receptor-! (PPAR!)3 is a
member of the nuclear hormone receptor superfamily. In addi-
tion to other PPAR isoforms, this superfamily also includes the
receptors for thyroid hormones, retinoids, steroid hormones,
and vitamin D (1, 2). PPAR! regulates gene transcription by
binding with the retinoid X receptors to specific DNA
sequences termed peroxisome proliferator response elements
(3). After ligand activation, PPAR! modifies its conformation,
which facilitates the release of corepressors and subsequent
binding of a distinct set of nuclear coactivators, thereby foster-
ing PPAR! action (3). Ultimately, formation of these transcrip-
tional complexes enables PPAR! transcriptional control of a
variety of biological processes, including insulin sensitivity (4).
Indeed, PPAR! exerts important modulatory actions upstream
of themajor inflammatory networks involvingAP-1 andNF-"B
transcriptional regulation (5).
PPAR! activation by thiazolidinediones (TZDs) markedly
improves insulin sensitivity in type 2 diabetic patients (6–9).
However, the molecular mechanisms responsible for PPAR!-
mediated insulin sensitization have been only partially defined.
Studies in tissue-specific PPAR! knock-out mice have gener-
ated insight into the role of different tissues in PPAR!-medi-
ated regulation of systemic insulin-stimulated glucose meta-
bolism (10) (2, 11). To date, the relevance of PPAR! in
maintaining systemic insulin sensitivity in adipose tissues has
been convincingly demonstrated. In fact, the PPAR!-mediated
adipogenesis associated with the capability for fatty acid trap-
ping has emerged as a major factor in protecting against non-
adipose tissue insulin resistance (12). Skeletal muscle expres-
sion of PPAR! has further been shown to contribute to
systemic insulin sensitivity bymaintaining intact insulin-medi-
ated glucose utilization in muscle (10). Indeed, PPAR! was
reported to directly coordinate glucoregulatory responses in
this tissue (11). However, the genetic network responsible for* This studywas supported inpart by EuropeanCommunity FP6PREPOBEDIA
Grant 201681, the European Foundation for the Study of Diabetes, the
Associazione Italiana per la Ricerca sul Cancro, and by Ministero
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these functions in skeletal muscle has not been completely elu-
cidated yet.
Phosphoprotein Enriched in Diabetes/Phosphoprotein
Enriched in Astrocytes (PED/PEA-15) is a scaffold cytosolic
protein widely expressed in most human tissues (13, 14). Early
studies indicated that PED/PEA-15 has an important role in
controlling glucose disposal in the skeletalmuscle by impacting
on the phospholipaseD/protein kinaseC signaling network (15,
16). Further investigations demonstrated that PED/PEA-15 is
commonly overproduced in individuals with type 2 diabetes as
well as in their euglycemic offspring, causing skeletal muscle
insulin resistance in these individuals (17). PED/PEA-15 cellu-
lar levels are regulated by ubiquitinylation and proteosomal
degradation (18). In addition, run-on experiments in cultured
cells from type 2 diabetic patients have demonstrated that PED/
PEA-15 overproduction is caused, at least in part, by transcrip-
tional abnormalities (13). More recent studies evidenced that
epigenetic changes at the PED/PEA-15 gene have a major role
in controlling its transcription (19). However, the molecular
details responsible for regulation of PED/PEA-15 transcription
as well as the abnormalities in these mechanisms occurring in
type 2 diabetes remain unclear.
In this report, we demonstrate that PPAR! represses the
transcription of the diabetes-associated gene ped/pea-15. We
found that PPAR! repression of this gene requires displace-
ment of the c-JUNcomponent of theAP-1 transcriptional com-
plex from the ped/pea-15 promoter. These findings identify
ped/pea-15 as a gene downstream of major PPAR!-regulated
inflammatory networks, whose control may be instrumental to
PPAR! action on glucose disposal by the skeletal muscle.
EXPERIMENTAL PROCEDURES
Materials—Rosiglitazone and pioglitazone (Ptz) were pur-
chased from Cayman Chemical (Ann Arbor, MI). 12-O-Tetra-
decanoylphorbol-13-acetate (TPA) and GW9662 were pur-
chased from Sigma. Solutions were prepared in dimethyl
sulfoxide (DMSO) and diluted 1:1000 into serum-free DMEM
immediately before use. PPAR!, c-JUN, and 14-3-3# antibodies
were purchased from Santa Cruz Biotechnology (Santa Cruz,
CA), and the PED/PEA-15 antibody was purchased from Cell
Signaling Technology (Danvers, MA). Oligonucleotides,
including the scrambled phosphorothioate oligodeoxynucle-
otide and the rat c-Jun antisense (20), were synthesized by
Sigma. [!-32P]dATP and 2-[1-14C]deoxy-D-glucose, were pur-
chased from PerkinElmer Life Sciences. The pPED2000-Luc
and pPED210-Luc constructs have been previously described
(21). Site-directed mutagenesis of the CRE-like site was
achieved using the QuikChange site-directed mutagenesis kit
according to the manufacturer’s instructions (Stratagene, La
Jolla, CA). The following oligonucleotides were validated by
EMSA and used to create the desired mutation: CREmut.F 5!-
CCGGCTCTGACATTGCCGGCCAGCCGGG-3! and CRE-
mut.R 5!-CCCGGCTGGCCGGCAATGTCAGAGCCGG-3!.
Mutant clones were screened by DNA sequencing. The
pcDNA3 expression vector containing the Myc-tagged PED/
PEA-15 has also been reported previously (22). The (PPRE)3-
tk-luciferase construct (23) was donated by Dr. Mitchell Lazar
(University of Pennsylvania). The dominant negative PPAR!
expression vector, the L468A/E471A h-PPAR! double mutant
(24), was donated by V. Krishna K. Chatterjee from University
of Cambridge, United Kingdom. The expression vector
(pCEFL) for c-Jun-HAwas provided byDr.Musti (University of
Cosenza, Italy).
Cell Culture Studies—L6 skeletal muscle cells and HeLa cells
were cultured inDulbecco’smodified Eagle’smedium (DMEM)
supplemented with 10% fetal bovine serum (FBS) and 1% pen-
icillin/streptomycin solution at 37 °C in a humidified 95% air
and 5% CO2 atmosphere. L6 myoblasts were plated at a density
of 3 " 104 cells/ml, and differentiation of confluent cells was
initiated by reducing the FBS content of the media to 2% with a
medium change every 48 h. Differentiation of myoblasts into
multinucleated myotubes was completed by 7 days after
medium change. Fused multinucleated myotubes were incu-
bated with the serum-depleted (0.5%) medium for 16 h and
treated with TZDs at the indicated concentrations for a further
24 h, although control cells received the vehicle alone in the
serum-depleted (0.5%) medium. L6 myoblasts were electropo-
rated with the Neon Transfection System (Invitrogen), and L6
myotubes andHeLa cells were transfected using Lipofectamine
2000 (Invitrogen), according to themanufacturer’s instructions
(15). All cell culture media and reagents were from Lonza
(Basel, Switzerland).
Glucose uptake in L6 cells was assayed as reported previously
(25). Briefly, the cells were incubated for 24 h in serum-free
medium supplementedwith 0.25% (w/v) bovine serumalbumin
(BSA) in the absence or presence of 1 $M Rtz. The cells were
rinsed in glucose-free HEPES buffer (5 mM KCl, 120 mM NaCl,
1.2 mM MgSO4, 10 mM NaHCO3, 1.2 mM KHPO4, and 20 mM
HEPES, pH 7.8, 2% albumin) and further exposed to 100 nM
insulin for 30 min. 2-Deoxy-D-[14C]glucose uptake was mea-
sured over a 10-min period, with nonspecific uptake deter-
mined in the presence of cytochalasin-B.
Animal Studies—5-Week-old male C57BL/6J mice were
hosted at the common facility of the University of NaplesMed-
ical School and had free access to water and food. For high fat
diet treatment, mice were fed a high fat diet with#60 cal % fat
or a standard diet with #10 cal % fat (Research Diets, New
Brunswick, NJ) (26) for 12 weeks. During the last 10 days, the
animals received either 10mg/kg/die Rtz or vehicle alone (0.5%
carboxymethylcellulose) by oral gavage. For insulin tolerance
testing,micewere fasted for 4 h and then subjected to intraperi-
toneal injection with insulin (0.75 milliunits g$1 of body
weight). Venous blood was subsequently drawn by tail clipping
at 0, 15, 30, 45, 60, 90, and 120 min as in Ref. 27. For intraperi-
toneal glucose tolerance testing, mice were fasted overnight
and then subjected to intraperitoneal injection with glucose
(2.0 g kg$1 of body weight). Venous blood was subsequently
drawn by tail clipping at 0, 15, 30, 45, 60, 90, and 120 min as in
Ref. 27. In overnight fasted mice, serum insulin concentrations
were measured by rat insulin RIA kit (Millipore, Billerica, MA)
(27). Blood glucose levelsweremeasuredwithAccu-Chek! glu-
cometers (Roche Applied Science). In overnight fasted mice,
analyses of serum triglycerides, total cholesterol, HDL choles-
terol, and LDL cholesterol were done on Horiba ABX Pentra
400 Chemistry Analyzer (HORIBA ABX, Montpellier, France).
The animals were sacrificed, and skeletal muscle tissues (gas-
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trocnemius) were removed, rinsed with 0.9% NaCl, frozen in
liquid nitrogen, and kept in$80 °C before harvesting.
Western Blot Analysis—Cells were solubilized by scraping
and passed 10 times through a 25-gauge needle in ice-cold lysis
buffer, supplemented with the Complete Protease Inhibitor
Mixture Tablets (Roche Applied Science). Lysates were clari-
fied by centrifugation at 16,000 " g for 10 min at 4 °C, and
protein concentration was determined using the protein assay
based on Bradford’s method (Bio-Rad) (28). Total cell extracts
in equal amounts were separated by SDS-PAGE and blotted on
nitrocellulose membranes (Millipore, Billerica, MA). Mem-
branes were blocked in 5% BSA, and specific proteins were
detected by incubation with appropriate primary and second-
ary antibodies (horseradish peroxidase-conjugated) in 150 mM
NaCl, 50 mM Tris, 0.5% Tween 20 (TBST). Protein bands were
visualized using an enhanced chemiluminescence (ECL) kit
(Thermo Scientific Pierce Protein Biology, Waltham, MA) and
quantified by the ImageJ software (a public domain and Java-
based image processing program developed at the National
Institutes of Health). Relative protein abundance was calcu-
lated after 14-3-3# normalization.
Real Time PCR Analysis—Total RNA was extracted with the
TRIzol reagent (Invitrogen), according to the manufacturer’s
protocol. Reverse transcription of 1 $g of total RNA was per-
formed using SuperScript III (Invitrogen), following the manu-
facturer’s instructions. Quantitative real time PCR was per-
formed in triplicate by using iQ SYBR Green Supermix on
iCycler real time detection system (Bio-Rad). Relative quantifi-
cation of gene expression was calculated by the %%Ct method
(29). Each Ct value was first normalized to the respective glyc-
eraldehyde-3-phosphate dehydrogenase (GAPDH) Ct value of
a sample to account for variability in the concentration of RNA
and in the conversion efficiency of the RT reaction. For copy
number analysis, the real time PCR amplification products for
ped/pea-15 and gapdh were cloned into the pGEM!-T easy
vector (Promega, Madison, WI), and calibration curves were
made from serial 10-fold dilutions of plasmid DNAs as
described previously (30). The mean slopes of the calibration
curves for the two genes were similar,$3.3 for ped/pea-15 and
$3.1 for gapdh, where a slope of $3.3 & 10% reflects an effi-
ciency of 100 & 10% of the PCR r, and the mean correlation
coefficient (R) for both of the curves was 0.99. The equations
drawn from the graph of the standard curves were used to cal-
culate the precise number of specific cDNA molecules present
in the samples (copy number variation).
Luciferase Assays—Cells were cotransfected with 2 $g of the
Firefly luciferase vector (pGL3 plasmids, Promega, Madison,
WI) and 1$g of the pRSV-%-galactosidase (Promega,Madison,
WI), as internal control to normalize for transfection efficiency.
In each reaction, the total amount of transfected DNAwas kept
constant at 5$g by using the empty expression vector pcDNA3
or PPAR!L468A/E471Amutant. 24 h after transfection, cells were
incubatedwith the serum-depleted (0.5%)medium for 16 h and
then exposed to serum-depleted (0.5%) medium supplemented
with vehicle (0.1% DMSO) or TPA (0.1 $M) in the absence or
presence of increasing concentrations of Rtz for 4 h. Luciferase
and %-galactosidase activities were measured with a luminom-
eter (Berthold Technologies, BadWildbad, Germany). Lucifer-
ase activities were divided by the respective %-galactosidase
activity and expressed as relative luciferase units.
Electrophoretic Mobility Gel Shift (EMSA) and Supershift
Assays—Nuclear extracts from HeLa cells were prepared as
described previously with minor modifications (31). Double-
stranded oligonucleotides were end-labeled with [!-32P]ATP
by T4 polynucleotide kinase (Promega, Madison, WI) accord-
ing to themanufacturer’s instructions. The radiolabeled probes
were purified by spin columns (Roche Applied Science). 5$g of
nuclear protein extracts from control and treated cells were
incubated with 100,000 cpm 32P-labeled oligonucleotide probe
in 25 mM HEPES, pH 7.4, 50 mM KCl, 10% glycerol (v/v), 5 mM
dithiothreitol (DTT), and 1 $g of poly(dI-dC) (GE Healthcare)
for 30min at room temperature in a final volume of 20$l. Upon
binding, protein-DNA complexes were separated on 6% non-
denaturing polyacrylamide gels at 120 V in 0.5" TBE buffer.
Gels were dried and further subjected to PhosphorImager anal-
ysis (Bio-Rad). In competition analysis, 25-, 50-, and 100-fold
molar excess of the unlabeled double strand oligonucleotide
was added to the reaction mixture prior to the addition of the
labeled probe. For the antibody supershift analysis, 1$g of anti-
bodywas added to the nuclear extracts prior to the radiolabeled
oligonucleotide.
FIGURE 1. PPAR! expression and function in L6 skeletal muscle cells.
A, 3T3-L1 fibroblasts, 3T3-L1 adipocytes, L6 myotubes, and HeLa cells were
lysed, and total protein extractswere separated by SDS-PAGE. The antibodies
used were specific for PPAR! and 14-3-3# as loading control. The autoradio-
graph shown is representativeof four additional experiments.B, L6myotubes
were cotransfected with PPRE3-tk-luc and pRSV-%-gal constructs as
described under “Experimental Procedures.” Upon transfection, the cells
were incubated in the absenceor presenceof the indicated concentrations of
Rtz. Luciferase and %-galactosidase activities were measured in cellular
extracts 24 h later. %-Galactosidase activity enabled the estimation of trans-
fection efficiency and assessment of relative luciferase values (RLU). Bars rep-
resent themeans& S.D. of three independent experiments.Asterisks indicate
statistically significant differences at a p' 0.001 level.
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Chromatin Immunoprecipitation Assay (ChIP)—ChIP assays
were performed as reported previously (21). Briefly, upon pro-
tein-DNA cross-linking, cells were lysed and sonicated to
achieve chromatin fragments ranging between 500 and 1000 bp
in size. The lysates were incubated with either c-JUN antibody
or a rabbit control IgG, and then complexes were isolated using
protein A-agarose/salmon sperm DNA (Millipore, Billerica,
MA). Immunoprecipitates were extensively washed and then
eluted by freshly prepared 1% SDS, 0.1 MNaHCO3 buffer. After
reversion of cross-linking, DNA was purified by the QIAquick
PCR purification kit (Qiagen, Hilden, Germany) followed by
PCR amplification. PCR products were resolved by 2% agarose
gel electrophoresis, revealed by ethidiumbromide staining, and
analyzed by densitometry using the ImageJ software (National
Institutes of Health).
Statistical Analysis—All data are presented as means & S.E.
Statistical differences were determined by one- or two-way
analysis of variance as appropriate, and Bonferroni post hoc
testing was performed when applicable. A p value '0.05 was
considered significant.
RESULTS
PPAR! Regulates ped/pea-15 Function in Muscle Cells—We
assessed PPAR! expression in the L6 skeletalmuscle cell line by
Western blot analysis. The PPAR-specific antibody detected
both the isoforms 1 and 2, which have a predicted molecular
mass of#53 and 57 kDa, respectively. In L6myotubes as well as
in HeLa cells, the !1 isoform was more abundant than the !2
isoform, although PPAR!2 was the most highly expressed iso-
form in 3T3-L1 adipocytes. At variance, 3T3-L1 fibroblasts
showed very low PPAR! levels (Fig. 1A). L6 cells were also
transfected with a construct featuring the PPAR response ele-
ment upstream from the luciferase gene (PPRE3-tk-luc). As
shown in Fig. 1B, treatment of these cells with increasing
amounts of the PPAR! agonist Rtz determined a significant
FIGURE 2. PPAR! repression of ped/pea-15 transcription. A, L6myotubeswere incubated in the presence of the indicated concentrations of Rtz (black bars)
or Ptz (gray bars) for 24 h. Total RNAwas obtained, and ped/pea-15 and gapdhmRNA levels weremeasured by qRT-PCR. Valueswere normalized for gapdh and
presented as fold decrease relative to the control (untransfected cells). B, L6myotubeswere incubated in the absence or presence of Rtz for 24 h. Total protein
extracts were separated by SDS-PAGE followed by immunoblottingwith PED/PEA-15 or 14-3-3# antibody, as indicated. The one presented is representative of
two additional experiments with very similar results. C, total RNAwas obtained fromgastrocnemius of C57BL/6Jmice treated or not with 10mg/kg/die Rtz for
10 days. The mRNAs were assessed by qRT-PCR. ped/pea-15 values were normalized for gapdh and expressed as fold decrease versus control. D, L6 myotubes
were preincubated with 10 $M GW9662 for 1 h or transfected with the PPAR!L468A/E471A mutant as described under “Experimental Procedures” and then
treatedwith 1$MRtz for 24 h. Total RNAwas obtained, and ped/pea-15 and gapdhmRNA levels weremeasured by qRT-PCR. Valueswere normalized for gapdh
and presented as fold decrease relative to the control. Bars represent the means & S.D. of three (A and D) and four independent experiments (B). Five
mice/group were used in C. Asterisks denote statistically significant differences (*, p' 0.05; **, p' 0.01, and ***, p' 0.001).
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increase in the promoter activity, indicating that PPAR! is tran-
scriptionally active in L6 cells.
PPAR! has been reported to regulate a number of genes con-
trollingmetabolic functions (32). Interestingly, in L6myotubes,
Rtz and Ptz repressed ped/pea-15 expression in a dose-depen-
dent manner, and this effect occurred both at mRNA (Fig. 2A)
and at protein levels (Fig. 2B). A comparable decrease in ped/
pea-15mRNA levels was also observed in the skeletal muscle of
Rtz-treatedC57BL/6Jmice (Fig. 2C). In addition, both pretreat-
ment of L6 cells with the PPAR! antagonist GW9662 and
transfection with the dominant negative PPAR! mutant,
PPAR!L468A/E471A, completely abolished the Rtz effect (Fig.
2D), indicating that TZDs inhibit ped/pea-15 expression via
PPAR!.
The known physiological importance of PED/PEA-15 in reg-
ulating glucose tolerance prompted us to further investigate the
molecular details of the TZDs action on ped/pea-15 function.
To this end, we transfected L6 cells with a myc-tagged PED/
PEA-15 cDNA driving the expression of the gene under the
control of the cytomegalovirus (CMV) promoter, and then we
exposed the cells to Rtz. As shown in Fig. 3A, Rtz did not affect
the levels of the exogenous PED/PEA-15 protein (21 kDa),
although it reduced the levels of the endogenous one (15 kDa).
Consistent with these findings, treatment with Rtz did not sig-
nificantly affect PED/PEA-15 protein levels in the skeletal mus-
cle of transgenic mice overexpressing this gene under the con-
trol of the exogenous %-actin promoter (Tgped), although it
reduced endogenous PED/PEA-15 protein levels up to 60% in
their wild-type littermates (Fig. 3B). Furthermore, as shown in
Fig. 3C, Rtz enhanced glucose uptake in wild-type L6 cells
(L6WT) but not in those cells expressing the exogenous PED/
PEA-15 (L6ped). Thus, it appeared that the endogenous ped/
pea-15 promoter is necessary for PPAR! regulation of the gene.
PPAR! Silences ped/pea-15 by Interfering with AP-1
Signaling—These findings led us to explore the molecular
mechanisms involved in PPAR! regulation of ped/pea-15 in
greater detail and to identify the PPAR! responding region at
the ped/pea-15 promoter. Previous studies in cells treated with
TPA, a known activator of both AP-1 and NF-"B, revealed
increased PED/PEA-15 expression (18). We have therefore
addressed the hypothesis that PPAR! reduces PED/PEA-15
transcription by transrepressing one or both of these transcrip-
tion factors. In silico analysis of the human PED/PEA-15 pro-
moter revealed the presence of a TGACATCA CRE-like site
between the positions$106 and$86 bp from the transcription
start site ((1). This sequence is known to bind the AP-1 tran-
scriptional complex (33). A caGGGActtt NF-"B-binding site
between positions$798 and$786 bp was also identified. Fur-
thermore, sequence alignment of the human and rat 5!-flanking
regions revealed that these two sequences are highly conserved,
suggesting they may perform a major role in regulating PED/
PEA-15 expression and prompted us to test the significance of
AP-1 and NF-"B in the PPAR!-dependent regulation of the
PED/PEA-15 promoter.
To this goal, we transfected HeLa cells with a reporter vector
featuring the luciferase gene downstream from the $1942 to
(58 bp of the proximal 5!-flanking region of the human PED/
PEA-15 gene (pPED2000). In these transfected cells, TPA up-
regulated the PED/PEA-15 promoter activity, achieving its
maximum effect within 4 h of exposure (Fig. 4A). Consistently,
a)2-fold increase in PED/PEA-15mRNA levels was also dem-
onstrated by quantitative RT-PCR (qRT-PCR) analysis (Fig.
4B). Furthermore, TPA effect on both PED/PEA-15mRNA lev-
els (Fig. 4C) and promoter activity (Fig. 4D) was significantly
inhibited by treating the cellswithRtz. In addition, the presence
FIGURE 3. Significance of ped/pea-15 promoter to PPAR!-dependent
repression. A, L6myotubeswere transfectedwith a pcDNA3 expression vec-
tor containing aMyc-tagged PED/PEA-15 cDNA under the control of the CMV
promoter. The cells were incubated in the presence of the indicated concen-
trations of Rtz for 24 h. Total protein extracts were separated by SDS-PAGE
and immunoblotted with a specific PED/PEA-15 antibody, which detected
both the endogenous (15 kDa) and the exogenous (21 kDa) protein. Results
are shown from a representative experiment; qualitatively similar data were
obtained in replicate experiments. B, transgenic mice overexpressing PED/
PEA-15 (Tgped; n * 6), and their nontransgenic littermates (WT; n * 6) were
treated with 10 mg/kg/die of Rtz for either 3 or 10 days, as indicated. Total
protein extracts from gastrocnemius were separated by SDS-PAGE followed
by immunoblotting with PED/PEA-15 or 14-3-3# antibody. Blots were
revealed by ECL, and autoradiography and the intensity of bands was quan-
titated by densitometry. C, L6 myotubes were transfected with a PED/PEA-15
cDNA (dark gray bars). Both L6wt and L6ped cells were incubated in the
absence or presence of 1$M Rtz for 24 h followed by stimulationwith 100 nM
insulin (Ins) for 30 min. 2-Deoxy-D-glucose (2-DG) uptake was assayed as
described under “Experimental Procedures.” Bars represent themeans& S.D.
of duplicate (B) and triplicate (C) determinations in three independent exper-
iments.Asterisksdenote statistically significant differences (*,p' 0.05; **,p'
0.01).
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of the PPAR! antagonist GW9662 as well as that of the domi-
nant negative PPAR! mutant, PPAR!L468A/E471A, enabled full
TPA effect on promoter activity during simultaneous treat-
ment with Rtz (Fig. 4D). These findings initially supported the
possibility that PPAR! regulation of PED/PEA-15 function
might involve AP-1 and/or NF-"B transcriptional control.
To further explore this hypothesis, we transfected HeLa cells
with either a PED/PEA-15 deletion construct lacking the
NF-"B-binding site but featuring an intact CRE-like site
(pPED210) or the same construct where the CRE-like site was
mutagenized (pPED210MUT). Interestingly, in the former case,
exposure to TPA induced a 2.5-fold enhanced transcriptional
activity, which was almost completely suppressed by Rtz treat-
ment (Fig. 5A). At variance, cells transfected with the CRE-like
mutagenized construct exhibited depressed basal promoter
activity with complete loss of TPA responsiveness, whether in
the absence or presence of Rtz. These observations led us to
hypothesize that AP-1 plays a major role in basal and PPAR!-
dependent regulation of PED/PEA-15 expression. Indeed, in
cells transfected with the pPED2000MUT construct, which fea-
tures the intact NF-"B site but the mutated CRE-like site, Rtz
treatment failed to repress TPA-induced PED/PEA-15 pro-
moter activity (Fig. 5B), suggesting that NF-"B is not involved
in the regulation of PED/PEA-15 expression by PPAR!.
EMSAs also revealed increased occupancy of the CRE-like
site at PED/PEA-15 promoter in lysates from TPA-treated as
compared with untreated HeLa cells (Fig. 6A, left). This CRE-
like site occupancy was dose-dependently inhibited by Rtz.
Importantly, supershift assays with a specific c-JUN antibody
revealed the presence of the AP-1 component c-JUN in the
binding complex at the CRE-like site (Fig. 6A, right). c-JUN
occupancy at the PED/PEA-15 promoter was also investigated
in living cells by ChIP assays. In these experiments, the cross-
linked chromatin was precipitated using the c-JUN antibody
followed by amplification of the CRE-like site at the human
PED/PEA-15 promoter. As shown in Fig. 6B, TPA exposure
determined the c-JUN association to the CRE-like site, which
was reduced by Rtz treatment in a dose-dependent manner.
FIGURE4.MechanismsofTPAregulationofped/pea-15promoteractivity.AandD,HeLacells, cotransfectedwith thepPED2000andpRSV-%-gal constructs,
were further transfected with the PPAR!L468A/E471A mutant or pretreated with 10$M GW9662 for 1 h and subsequently incubated in the absence or presence
of 0.1$M TPA and 1$M Rtz for 4 h, as indicated. Luciferase activities weremeasured and normalized for%-galactosidase activities. Bars represent themeans&
S.D. of four independent experiments each performed in duplicate. B and C,HeLa cells were incubated in the absence or presence of 0.1$M TPA and 1$M Rtz
for 4 h, as indicated. PED/PEA-15mRNA levels were subsequently quantitated by qRT-PCR, and values were normalized for GAPDH of the same samples and
shown as fold increase relative to untreated cells. Bars represent themeans& S.D. of three independent experiments. Asterisks denote statistically significant
differences (***, p' 0.001).
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This effect was not due to a decrease in TPA-induced expres-
sion of c-JUN in HeLa cells (Fig. 6C).
PPAR! Represses ped/pea-15 Expression via AP-1 in L6
Cells—Based on ChIP assays, Rtz as well as Ptz treatment
decreased c-jun binding to the CRE-like site also in L6 myo-
tubes (Fig. 7A), confirming the major role of AP-1 in the ped/
pea-15 down-regulation by PPAR! also in skeletal muscle cells.
Importantly, in these experiments, the two TZDs did not affect
the binding of the NF-"B subunit p65 to its binding site on the
ped/pea-15 promoter (Fig. 7B).
In L6 cells, the overexpression of c-JUN (Fig. 8A) slightly
increased ped/pea-15 expression in untreated cells (Fig. 8B).
However, higher levels of ectopic c-JUN bypassed the down-
regulation of ped/pea-15 due to PPAR! (Fig. 8B). In parallel,
activated PPAR!was not able to displace c-JUN from the CRE-
like site at ped/pea-15 promoter when it was overexpressed in
L6 cells (Fig. 8C). After c-jun silencing (Fig. 8A), L6 cells showed
a significantly lower expression of ped/pea-15 compared with
wild-type cells no longer reduced by both Rtz and Ptz (Fig. 8B),
supporting the major role of AP-1 in ped/pea-15 down-regula-
tion by PPAR! also in skeletal muscle cells.
PPAR!Decreases ped/pea-15 Expression inHigh Fat Diet-fed
Mice—The in vivo significance of ped/pea-15 regulation by
PPAR! agonists was further explored in mice subjected to a
high fat diet regimen for 12 weeks. As shown in Table 1, these
mice became dyslipidemic and developed significant hyperin-
sulinemia and insulin resistance. Interestingly, these changes
were accompanied by a 2.5-fold increase in ped/pea-15 expres-
sion in their skeletal muscle. Further treatment of these mice
FIGURE5.RoleofAP-1 inPPAR!-mediated regulationofped/pea-15 tran-
scription.HeLa cellswere cotransfectedwithpPED210 (A) or pPED2000 (B) or
the versions of these constructs featuring the mutagenized CRE-like site
(pPED210MUT andpPED2000MUT, respectively), in addition to pRSV-%-gal con-
struct. The cellswere then incubated in the absenceorpresenceof 0.1$MTPA
and 1$M Rtz for 4 h. Luciferase activities were normalized to %-galactosidase
activities. Data are presented as means & S.D. of four independent experi-
ments, each in duplicate. Asterisks denote statistically significant differences
(***, p' 0.001).
FIGURE6.RtzeffectonTPA-inducedbindingofAP-1 to theCRE-like siteat
PED/PEA-15 promoter. A, HeLa cells were incubated in the absence or pres-
ence of 0.1$M TPA and the indicated concentrations of Rtz for 4 h (lanes 1–4).
Nuclear protein extracts were incubated with a 32P-labeled oligonucleotide
encompassing the CRE-like site at PED/PEA-15 promoter. Nuclear protein
extracts from TPA-treated cells were preincubated with c-JUN antibody for
different times (1and4h, lanes 6and7) beforeadding the radiolabeledprobe.
The reactionmixtures were separated on 6% nondenaturing polyacrylamide
gels, and dried gels were revealed by autoradiography. The autoradiographs
shown are representative of four independent experiments. B, HeLa cells
were incubated in the absence or presence of TPA and Rtz , as indicated;
soluble chromatin was prepared and immunoprecipitated with either c-JUN
or nonspecific IgG antibody. Chromatin immunoprecipitation was followed
by PCR amplificationwith primers designed for theCRE-like site at the human
PED/PEA-15 promoter. Amplification products were separated on agarose
gels and revealed by ethidiumbromide. The photograph shown is represent-
ative of five independent experiments.C, cells were incubated in the absence
or presence of TPA and Rtz, as indicated. Total protein extracts were sepa-
rated by SDS-PAGE, transferred to nitrocellulose filters, and immunoblotted
with c-JUN or 14-3-3# antibody. Blots were revealed by ECL and autoradiog-
raphy. The autoradiographs shown are representative of three independent
experiments.
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with Rtz for 10 days improved dyslipidemia and plasma insulin
levels. Based on the determination of glucose areas under the
curves during the accomplishment of insulin tolerance tests,
insulin sensitivity was also rescued by Rtz. Simultaneously ped/
pea-15 mRNA levels were significantly reduced, further sup-
porting the important role of ped/pea-15 in Rtz action in vivo.
DISCUSSION
The relevance of adipose tissue versus skeletal muscle in
mediating PPAR! function in glucose tolerance has been
debated (10, 11, 34). PPAR! is a master regulator of adipogen-
esis (7, 35) whose induction, associated with the capability for
fatty acid trapping, has been shown to represent an important
contributor to the maintenance of systemic insulin sensitivity
(12, 36). However, studies in mice with targeted loss of PPAR!
in the skeletal muscle revealed development of severe insulin
resistance in these animals (2). Despite development of fat and
liver insulin resistance (2, 11), evidence was also obtained that,
in these mice, PPAR! directly coordinates glucoregulatory
responses in the skeletal muscle and this action is needed for
the beneficial effects of PPAR! agonists in ameliorating insulin
resistance conditions (10). Comprehensive and unbiased
mRNA profiling studies in rats revealed that PPAR! activation
has coordinate effects on gene expression in multiple insulin-
sensitive tissues, with regulation of specific gene panels in each
of these tissues (37).
However, in the skeletal muscle, the panel of the genes regu-
lated by PPAR! is still incomplete,making themolecular details
of PPAR! action on muscle glucoregulatory function unclear.
In this study, we report that inmouse skeletal muscle tissue and
FIGURE 7. TZD effect on ped/pea-15 promoter occupancy by c-jun and
p65. L6myotubeswere incubatedwith either 10$M Rtz or 10$M Ptz for 24 h,
as indicated. Soluble chromatin was prepared and immunoprecipitated with
c-JUN, p65, or nonspecific IgG antibodies. Chromatin immunoprecipitation
was followed by PCR amplification with primers designed for either the CRE-
like site (A) or the NF-"B-binding site (B) at the rat ped/pea-15 promoter.
Amplification products were separated by agarose gels and revealed by
ethidium bromide. Bars representmeans& S.D. of three independent exper-
iments. Asterisks denote statistically significant differences (**, p' 0.01; ***,
p' 0.001).
FIGURE 8. Mechanism of TZD-dependent regulation of ped/pea-15
expression. L6myotubeswere transiently transfectedwith the vector pCEFL
containing c-JUN cDNA or c-JUN phosphorothioate antisense oligonucleo-
tides, as indicated. Upon transfection, the cells were incubatedwith either 10
$MRtz or 10$MPtz for 24h.A, cellswere lysed, and total protein extractswere
separated by SDS-PAGE followed by immunoblotting with c-JUN or 14-3-3#
antibody. Blots were revealed by ECL and autoradiography. B, total RNA was
obtained, and then ped/pea-15 and gapdh mRNA levels were measured by
qRT-PCR. Bars represent themeans& S.D. of three independent experiments.
Asterisks indicate statistically significant differences (*, p ' 0.05; ***, p '
0.001). C, L6 myotubes were transiently transfected with the pCEFL contain-
ing a c-JUN cDNA before incubating with either 10 $M Rtz or 10 $M Ptz for
24 h. Soluble chromatin was prepared and immunoprecipitated with either
c-JUN or nonspecific IgG antibody. Chromatin immunoprecipitation was fol-
lowed by PCR amplification with primers designed for the CRE-like site at the
rat ped/pea-15 promoter. Amplification products were separated on agarose
gels and revealed by ethidiumbromide. The photograph shown is represent-
ative of three further experiments.
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in L6 skeletal muscle cell line the PPAR! agonists Rtz and Ptz
repress the expression of ped/pea-15, identifying this gene as a
novel downstream target of PPAR!. Indeed, either preincuba-
tion with the PPAR! antagonist GW9662 or transfection with
the dominant negative PPAR!mutant, PPAR!L468A/E471A (24),
completely blocked the Rtz effect.
Previous studies in mice and in humans demonstrated that
PED/PEA-15 serves as a physiological regulator of glucose tol-
erance (13, 38). PED/PEA-15 is transcriptionally up-regulated
in type 2 diabetics as well as in their euglycemic offspring (17),
determining insulin resistance in glucose disposal in the skele-
tal muscle mass (15). The mechanisms of PED/PEA-15 tran-
scriptional control have been only partially elucidated, but its
repression by PPAR! agonists in skeletal muscle may contrib-
ute to the beneficial effects of these agents when administered
to individuals with abnormalities in glucose tolerance. In sup-
port of these conclusions, we observed that, together with its
action on ped/pea-15 transcription, Rtz improved insulin-stim-
ulated glucose uptake in the L6 cells, although both these effects
were simultaneously impaired in cells expressing ped/pea-15
under the control of an exogenous promoter. In addition, the in
vivo studies reported in this work now show that high fat diet
raised the expression of ped/pea-15 in parallel with the devel-
opment of insulin resistance, whereas Rtz simultaneously
reversed both of these effects.
The finding that ped/pea-15 is a target of PPAR! prompted
us to further explore in vitro the details of PPAR! regulation of
this gene. Previous studies in cells treated with TPA, a known
activator of both AP-1 and NF-"B, revealed increased ped/
pea-15 expression (18), supporting the hypothesis that PPAR!
brakes ped/pea-15 transcription by transrepressing one or both
of these transcription factors. Indeed, in the course of this
study, we have functionally validated the presence of binding
sequences for AP-1 and NF-"B at the promoter of PED/PEA-
15, and the anti-inflammatory action of PPAR! is known to be
mediated to a major extent via transrepression of these factors
(39). Interestingly, supershift and ChIP experiments revealed
that Rtz reduced ped/pea-15 promoter occupancy by the c-jun
moiety of theAP-1 transcriptional complex. In contrast, NF-"B
presence at ped/pea-15 promoter was unaffected in TZD-
treated cells, indicating high specificity in the PPAR!-depen-
dent transcriptional control of ped/pea-15. The observation
that PPAR! inhibits Jun/AP-1 binding to DNA suggests a
potential direct protein-protein interaction between PPAR!
and c-Jun. A similar negative interference with AP-1 activity
has been described for other nuclear receptors, such as the ret-
inoic acid receptor (40) and the glucocorticoid receptor (41). In
these reports, both the glucocorticoid receptor and retinoic
acid receptor were shown to form a nonproductive complex
with c-jun, leading to a decrease of AP-1 binding activity. Alter-
natively, PPAR! could block or destabilize an interaction
between c-Jun and a cellular factor that facilitates DNA bind-
ing. Constructs bearing mutations at the CRE-like site of PED/
PEA-15 promoter, but notwithin theNF-"B-binding site, failed
in affecting promoter activity when AP-1 and NF-"Bwere acti-
vated by TPA. Thus, AP-1 but not NF-"B is necessary for
PPAR! control of thePED/PEA-15 transcription. Furthermore,
Rtz treatment in cells upon silencing of c-jun showed no effect
on ped/pea-15 expression, indicating that c-jun transrepres-
sion is sufficient for the PPAR! action. Themechanism respon-
sible for the Rtz effect on ped/pea-15 promoter occupancy by
c-jun was not based on changes in the levels of c-jun itself.
Alternatively, Rtz might impair ability of c-jun to bind to the
ped/pea-15 promoter, as forcing its occupancy by c-jun over-
expression blocked the Rtz repression of ped/pea-15.
The chronic low grade inflammation induced by obesity is
well recognized as a key trait of type 2 diabetes (42), as a number
of inflammatory pathways are activated in classical insulin tar-
get tissues of these individuals (43, 44). These signaling cas-
cades include the JNK/AP-1 network that is known to be down-
regulated by PPAR! (39). However, genes that are ultimately
involved in the impairment of glucose tolerance induced by
inflammatory stimuli are still largely unknown.We now report
that ped/pea-15 expression is controlled by physiological levels
of c-jun in the cells. Indeed, c-jun silencing with specific anti-
sense impairs basal ped/pea-15 expression. In addition, PPAR!
activating anti-inflammatory agents regulate ped/pea-15 by
reducing c-jun occupancy at its promoter. These findings iden-
tify ped/pea-15 as a gene whose transcription may change in
response to common abnormalities typical of the low grade
TABLE 1
Rosiglitazone effects on biochemical parameters of mice subjected to different dietary regimens
All data are presented as means& S.E. Statistical differences were determined by one- or two-way analysis of variance as appropriate, and Bonferroni post hoc testing was
performedwhen applicable. A p value of'0.05was considered significant. ITT indicates insulin tolerance test; AUC indicates area under curve; CNV indicates copy number
variation; CHOL indicates serum total cholesterol; TG indicates serum triglycerides. Data are means& S.E. STD indicates standard diet mice; HFD indicates high fat diet
mice; HFD(R indicates high fat diet mice after treatment with rosiglitazone 10 mg/kg/10 days, oral gavage.
STD (n" 10) HFD (n" 8) HFD#R (n" 6)
Body weight 28.51& 0.99 g 39.11& 1.30 ga 39.84& 2.27 g
Food intake 3.16& 0.09 g/mouse/day 2.87& 0.2 g/mouse/day 2.40& 0.2 g/mouse/day
AUC ITT 9343.5& 424.5 mg/dl"120 min 21517.5& 1812.7 mg/dl"120 mina 14817& 1038.5 mg/dl"120 minb
PED/PEA-15 2.81& 2.1E-05 CNV 6.77& 1.23E-04 CNVb 5.25& 7.75E-05 CNVc
CHOL 102.5& 6.71 mg/dl 207.33& 17.48 mg/dlb 130.8& 15.73 mg/dlc
TG 95.4& 6.64 mg/dl 204.23& 26.74 mg/dlb 83.86& 9.97 mg/dlb
HDL 47.16& 6.70 mg/dl 68.87& 11.10 mg/dl 57.74& 5.33 mg/dl
LDL 6.25& 1.10 mg/dl 15.40& 2.30 mg/dld 6.83& 0.68 mg/dlc
Glucose 107& 6.0 mg/dl 180& 11 mg/dla 163& 6.0 mg/dlc
Insulin 0.36& 0.13 ng/ml 1.09& 0.2 ng/mla 0.68& 0.32 ng/mlc
a Significant differences were between high fat diet mice versus standard diet mice and between high fat diet mice after treatment with rosiglitazone versus high fat diet mice.
p&0.001.
b p&0.01.
c Data are indicated by t test.
d p&0.05.
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unresolved inflammation associated with type 2 diabetes. Fur-
ther studies assessing ped/pea-15 functionmay offer previously
unrecognized opportunities to identify these abnormalities.
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